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1. INTRODUCTION 
 
 
1.1  Acute myeloid leukemia  
 
Acute myeloid leukemia (AML) is a group of heterogeneous hematopoietic 
neoplasms characterized by the clonal proliferation of myeloid precursors, as a result 
of the loss of ability to respond to normal control mechanisms of cell proliferation and 
differentiation into more mature cells. The annual incidence of AML is approximately 
4 cases per 100,000 population (Deschler and Lubbert, 2006). Although the disease 
occurs at a young age, the median age of diagnosis is 70 years (Estey and Dohner, 
2006, Juliusson et al., 2009). 
 
1.1.1 Etiology and Pathophysiology of AML 
Haematopoiesis includes all the processes of proliferation and differentiation of the 
progenitor hematopoietic stem cells into more mature cells, myelocytes, lymphocytes, 
and megakaryocytes. Creating and maintaining appropriate conditions in the 
microenvironment of the bone marrow (BM), is of great importance in order to 
preserve an effective haematopoiesis (Colmone et al., 2008). In AML, the 
differentiation of myeloid progenitor cells is impaired and the apoptotic mechanisms 
are inhibited. This arrest in maturation results in uncontrolled proliferation and 
accumulation of myeloid immature cells (blasts) in the BM and in the peripheral blood 
(PB), as well as in the infiltration of other tissues, referred to as extramedullary 
disease (Ohanian et al., 2013). Often this leads to hematopoietic insufficiency 
(anemia, neutropenia, thrombocytopenia) with or without leucocytosis, due to BM 
failure.  
AML is clinically and biologically, a heterogeneous group of diseases, as a result of 
the large number of genetic and epigenetic events (Gutierrez and Romero-Oliva, 
2013, Popp and Bohlander, 2010). A great deal of evidence suggests that proto-
oncogenes and other growth-promoting genes such as those encoding for cytokines 
or their receptors, play an important role in leukemogenesis. In this evolutionary 
process genetic changes such as chromosomal aberrations or deletions may alter 
the regulation and the function of the proto-oncogenes and of the growth-promoting 
genes (Irons and Stillman, 1996). Intensive research activity has led to the 
conclusion that translocations observed in leukemias, may take place early in the 
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process of leukemogenesis since they appear to be stable and balanced within the 
leukemic clone (Kennedy and Barabe, 2008). 
Several risk factors have been associated with the development of AML. These 
include age, genetic disorders, as well as exposure to viruses, to ionizing radiation, to 
chemicals and to other occupational hazards (Sandler and Ross, 1997). Previous 
exposure to cytotoxic therapy with alkylating agents and topoisomerase II inhibitors 
(Momota et al., 2013, Baehring and Marks, 2012), has been reported to increase the 
incidence of leukemia, and has been related to specific cytogenic changes: deletions 
or loss of 7q or 5q as well as 11q23 chromosomal abnormalities respectively (Tang 
et al., 2012, Ezoe, 2012). Additionally, exposure to benzene (Irons et al., 2013) and 
cigarette smoking are also possible etiological factors (Sandler and Collman, 1987, 
Pogoda et al., 2002, Smith et al., 2011). Despite these associations, at the present 
time only 1-2% of the diagnosed leukemias can be attributed to exposure to these 
agents (Fernberg et al., 2007). 
 
1.1.2 Classification of AML 
In 1976, a new morphologic classification for acute leukemias was proposed by a 
working committee of French, American and British haematologists. 
Since its introduction this system known as FAB (French-American-British) 
classification has been widely accepted internationally. It is based on Romanovsky-
stained blast morphology and on cytochemical stains (Bennett et al., 1976). At that 
time FAB classification required the presence of 30% blasts in bone marrow, as a 
criterion of diagnosis. It divides the AML into eight subtypes depending on the degree 
of maturation of the particular myeloid lineage involved. The distinction is based on 
the morphologic appearance of the blasts and their reactivity with the histochemical 
stains. Additionally, immunologic methods have been incorporated into the diagnostic 
criteria for some FAB subgroups (Lowenberg et al., 1999) (Table 1). 
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Table 1: FAB classification of AML 
FAB 
SUBTYPE COMMON NAME                            
(% OF CASES) 
RESULTS OF STAINING 
ASSOCIATED 
TRANSLOCATIONS 
AND 
REARRANGEMENTS 
(% OF CASES) 
GENES 
INVOLVED 
  MYELO-
PEROXI-
DASE 
SUDAN 
BLACK 
NON   
SPECIFIC 
ESTERASE 
  
M0 Acute 
myeloblastic 
leukemia with 
minimal 
differentiation 
(3%) 
- - -* Inv(3q26) and 
t(3;3)(1%) 
EVI1 
M1 Acute 
myeloblastic 
leukemia 
without 
maturation (15-
20%) 
+ + -   
M2 Acute 
myeloblastic 
leukemia with 
maturation (25-
30%) 
+ + - t(8;21)(40%), 
t(6;9)(1%) 
AML1-ETO,            
DEK-CAN 
M3 Acute 
promyelocytic 
(5-10%) 
+ + - t(15;17)(98%), 
t(11;17)(1%), 
t(5;17)(1%) 
PML-RARα, 
PLZF-RARα, 
NPM1-RARα 
M4 Acute 
myelomonocytic 
leukemia (20%) 
+ + + 11q23(20%), 
inv(3q26) and 
t(3;3)(3%), 
t(6;9)(1%) 
MLL, DEK-
CAN, EVI1 
M4E0 Acute 
myelomonocytic 
leukemia with 
abnormal 
eosinophils (5-
10%) 
+ + + Inv(16), 
t(16;16)(80%) 
CBFβ-MYH11 
M5 Acute 
monocytic 
leukemia (2-
9%) 
- - + 11q23(20%), 
t(8;16)(2%) 
MLL, MOZ-
CBP 
M6 Erythroleukemia 
(3-5%) 
+ + -   
M7 Acute 
megakaryocytic 
leukemia (3-
12%) 
- - +† t(1;22)(5%) Unknown 
*Cells are positive for myeloid antigen (e.g., CD13 and CD33). 
†Cells are positive for a-naphthylacetate and platelet glycoprotein IIb/IIIa or factor VIII–related 
antigen and negative for naphthylbutyrate 
(Adapted from NEJM (Lowenberg et al., 1999)) 
 
Over the years, many large clinical studies highlighted the value of cytogenetic 
abnormalities in acute leukemias, thus requiring the revision of FAB classification. 
The importance of genetic events to diagnose and treat acute leukemia became 
widely accepted and a new classification was proposed from World Health 
Organization (WHO), in 2001 (Table 2). In this late classification acute leukemias are 
divided into 4 major groups. The genetic aberrations play a key role and the 
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percentage of blasts required for diagnosis of AML is lowered from 30% to 20% in PB 
and/or the BM aspirate. Exceptions include AML with t(8;21), inv(16) or t(15;17), in 
which the diagnosis of AML is made in spite a blast percentage in the BM<20%. This 
classification includes the genetic aberrations and immunophenotyping as major 
defining features in addition to morphology (Vardiman et al., 2002).  
 
Table 2: WHO classification of AML (WHO 2001) 
(Adapted from Blood journal, (Vardiman et al., 2002)) 
 
Since 2001, there has been considerable progress in understanding the biology of 
the disease. The discovery of many molecular abnormalities in myeloid neoplasms 
and the need for a common language between clinicians and laboratory investigators 
WHO classification of AML 
Acute myeloid leukemia with recurrent genetic abnormalities 
 Acute myeloid leukemia with t(8;21)(q22;q22),(AML1/ETO) 
 Acute myeloid leukemia with abnormal bone marrow eosinophils 
inv(16)(p13q22) or t(16;16)(p13;q22),(CBFβ/MYH11) 
 Acute promyelocytic leukemia with t(15;17)(q22;q12)(PML/RARa) and 
variants 
 Acute myeloid leukemia with 11q23 (MLL) abnormalities 
 
Acute myeloid leukemia with multilineage dysplasia 
 Following MDS or MDS/MPD 
 Without antecedent MDS or MDS/MPD, but with dysplasia in at least 
50% of cells in 2 or more myeloid lineages 
 
Acute myeloid leukemia and myelodysplastic syndromes, therapy related 
 Alkylating agent/radiation related-type 
 Topoisomerase type II inhibitor-related (some may be lymphoid) 
 Others 
 
Acute myeloid leukemia not otherwise categorised 
        Classify as: 
 Acute myeloid leukemia minimally differentiated 
 Acute myeloid leukemia without maturation 
 Acute myeloid leukemia with maturation 
 Acute myelomonocytic leukemia 
 Acute monoblastic/acute monocytic leukemia 
 Acute erythroid leukemia (erythroid/myeloid and pure erythroleukemia) 
 Acute megakaryoblastic leukemia 
 Acute basophilic leukemia 
 Acute panmyelosis with myelofibrosis 
 Myeloid sarcoma 
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has led to the publication of another revision of the classification of hematologic 
neoplasms (Vardiman et al., 2009, Dohner et al., 2010). It has been published as part 
of the 4th edition (Vardiman et al., 2009) of the WHO, where new categories as well 
as new provisional entities have been incorporated (Table 3). 
 
Table 3: Acute myeloid leukemia and related precursor neoplasms, and acute 
leukemias of ambiguous lineage (WHO 2008)  
Categories 
Acute myeloid leukemia with recurrent genetic abnormalities 
 AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
 Acute promyelocytic leukemia with t(15;17)(q22;q12); PML/RARA 
 AML with t(9;11)(p22;q23) MLLT3-MLL 
 AML with t(6;9)(p23;q34); DEK-NUP214 
 AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
 AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
 Provisional entity: AML with mutated NPM1 
 Provisional entity: AML with mutated CEBPA 
Acute myeloid leukemia with myelodysplasia-related changes 
Therapy related myeloid neoplasms 
Acute myeloid leukemia, not otherwise specified (NOS) 
 Acute myeloid leukemia with minimal differentiation 
 Acute myeloid leukemia without maturation 
 Acute myeloid leukemia with maturation 
 Acute myelomonocytic leukemia 
 Acute monoblastic/monocytic leukemia 
 Acute erythroid leukemia 
    Pure erythroid leukemia 
    Erythroleukemia, erythroid/myeloid 
 Acute megakaryoblastic leukemia 
 Acute basophilic leukemia 
 Acute panmyelosis with myelofibrosis (syn.: acute myelofibrosis; acute 
myelosclerosis) 
Myeloid sarcoma (syn.: extramedullary myeloid tumor; granulocytic sarcoma; 
chloroma) 
 Myeloid proliferations related to Down syndrome 
 Transient abnormal myelopoiesis (syn.: transient myeloproliferative disorder) 
 Myeloid leukemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
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Table 3: Acute myeloid leukemia and related precursor neoplasms, and acute 
leukemias of ambiguous lineage (WHO 2008) (continued) 
Acute leukemias of ambiguous lineage 
 Acute undifferentiated leukemia 
 Mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR-ABL1 
 Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged 
 Mixed phenotype acute leukemia, B/myeloid, NOS 
 Mixed phenotype acute leukemia with, T/myeloid NOS 
 Provisional entity: Natural killer (NK)-cell lymphoblastic leukemia/lymphoma 
 
(Adapted from Blood journal (Dohner et al., 2010)) 
 
1.2 Two-hit model of AML 
 
The pathogenesis of AML requires a series of genetic events (Jacobs, 1991, Dohner 
and Dohner, 2008). The specific mutational events required for this progression are 
not currently well defined. Based on experimental data from mouse bone marrow 
transplantation models, G.Gililland (Gilliland, 2001) proposed the “two-hit model” of 
leukemogenesis. According to this hypothesis, AML is the consequence of 
collaboration of at least two classes of mutations (Fig 1).  
 
 class I mutations: the first type of genetic lesion involves mutations that 
disturb the signal transduction pathways, favouring the proliferation and/or the 
survival of the cells. Already recognised mutations belonging to this category 
are: 
 Mutations leading to continuous activation of FLT3 receptor 
FLT3 is a transmembrane receptor and belongs in PDGFR subfamily 
(class III) of tyrosine kinase receptors which also include PDGFRA, 
PDGFRB, FMS and KIT (Small, 2006, Levis and Small, 2003). These 
receptors present the following common structure: a) 5 extracellular 
immunoglobulin domains, b) a transmembrane domain, c) a 
juxtamembrane domain and d) an intracellular tyrosine kinase domain 
(TK) (Frohling et al., 2002). FLT3 receptor is expressed in progenitor 
stem cells and plays a major role in survival, proliferation and 
differentiation through signal transduction pathways like 
RAS/Raf/Mek/Erk or STAT (Small, 2006). In AML two types of 
mutations have been recognized: 
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a) mutations of the internal tandem duplication (ITD)(FLT3-ITD) seen 
in 23% of patients with AML (Small, 2006). 
b) point mutations which usually involve codon 835 (FLT3-Asp835) of 
the kinase domain and is found in 8-12% of the AML patients 
(Small, 2006). 
The presence of FLT3 mutations is of major clinical significance. 
Patients with normal karyotype (NK) harboring the mutation FLT3-ITD 
have an inferior outcome (Schlenk et al., 2008, Kottaridis et al., 2003, 
Gale et al., 2008).  
 Mutations in the RAS gene family 
RAS gene encodes a G protein, which plays a major role in signal 
transduction, cell proliferation and malignant transformation.  
Two types of mutations are recognized:  
a) NRAS mutations are found in 9-14% of cytogenetically normal 
AML adult patients (Dohner, 2007), in about 40% of patients with 
core binding factor (CBF) AML and in 25% of patients with inv(3) 
AML (Dohner and Dohner, 2008).  
b) KRAS mutations are found in 5-17% of CBF AML (Dohner and 
Dohner, 2008). 
 JAK2V617F mutation 
JAK2V617F mutation is responsible for the increase activity of 
JAK/STAT signaling pathway which will result in the uncontrolled cell 
proliferation and survival (Kralovics et al., 2005, Schnittger et al., 
2007a) (the mechanism is analyzed in paragraph 1.4, page 17).  
 KIT mutations 
C-KIT is a receptor of tyrosine kinase (RTK) with a central role in 
hematopoiesis and in leukemogenesis (Malaise et al., 2009, Becker et 
al., 2008). Mutations in the tyrosine kinase domain at codon 816 (KIT-
D816) are present in about one-third of CBF leukemias (Zheng et al., 
2009, Cairoli et al., 2006, Paschka and Dohner, 2013).  
Recent studies indicate the adverse effect of the mutation, in the 
outcome of patients with t(8;21) (Cairoli et al., 2006, Schnittger et al., 
2006b). KIT mutations have negative impact on survival and event 
free survival in these patients (Schnittger et al., 2006b), while the 
impact of the mutation in patients with inv(16) is not clear (Paschka 
and Dohner, 2013, Kim et al., 2013). 
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 Class II mutations: according to the model that is proposed from Gililland, the 
second type of genetic lesion involves mutations affecting transcription factors 
and/or the transcriptional co-activation complex. This will lead to the 
impairment of the differentiation process (Dohner and Dohner, 2008). Known 
mutations in this category are: 
 Mutations in CEBPA 
The CCAAT enhancer binding protein alpha (CEBPA) gene encodes a 
member of the basic region leucine zipper (bZIP) transcription factors 
important for the differentiation of myeloid cells (Nerlov, 2004). The 
frequency of CEBPA mutations in NK-AML is 10-18% (Dufour et al., 
2010, Dohner and Dohner, 2008) and the presence of biallelic 
mutation has been associated with a better overall survival (OS) 
(Dufour et al., 2010, Dufour et al., 2012, Taskesen et al., 2011). 
 NPM1 mutations 
Mutations occurring in exon 12 of the nucleophosmin 1 gene (NPM1) 
are the most frequent genetic abnormalities in patients with de novo 
AML-NK (60%) (Falini et al., 2005, Falini et al., 2007a). Falini et al 
showed that the most common NPM1 mutation is the duplication of 
TCTG tetranucleotide named mutation A (Falini et al., 2007b). NPM1 
is located in the nucleolus and shuttles continuously between nucleus 
and cytoplasm. It is associated with the nucleolar ribonucleoprotein 
(ribosome biogenesis) (Falini et al., 2007b, Sportoletti, 2011).  
Patients with NPM1 mutations without FLT3-ITD have higher 
remission rates and favorable relapse-free survival (RFS) and OS 
(Dohner et al., 2010, Estey, 2013).  
 Fusion genes resulting from translocations t(8;21), inv(16)/t(16;16) 
and t(15;17) 
Leukemias with t(8;21)(q22;q22) (described in paragraph 1.3) and 
inv16(p13;q22)/t(16;16)(p13;q22), are known as core binding factor 
(CBF) leukemias and belong to the favorable cytogenetic risk group 
(Dohner and Dohner, 2008, Yin et al., 2012). 
The reciprocal translocation t(15;17)(q22;q21), characterizes acute 
promyelocytic leukemia (APL) and has as result the formation of PML-
RARA hybrid gene. PML-RARA is detected in 98% of APL cases. 
APL is a unique entity and the most curable myeloid leukemia (Lo-
Coco et al., 2008). The early detection and molecular monitoring of 
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PML-RARA fusion transcripts, is of crucial importance, since molecular 
relapse predicts hematological relapse (Grimwade and Lo Coco, 2002).  
 
Figure 1: The two hit model of AML  
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1.3 Acute myeloid leukemia with translocation t(8;21) 
 
1.3.1 Clinical features associated with t(8;21) leukemia 
AML cases with t(8;21) constitute about 5% of all AML cases (Vardiman et al., 2009). 
According to the last WHO classification (Vardiman et al., 2009), the translocation 
can be observed in about 10% of AML M2 FAB subtype, and in about 6% of AML M1 
FAB subtype (Peterson et al., 2007). It is one of the most important clinical subtypes 
in AML (Rowley, 2000, Ferrara and Del Vecchio, 2002). 
From a clinical point of view, AML with t(8;21) tends to occur in patients of a younger 
age (mostly <60 years) and is usually associated with a high remission rate and a 
prolonged disease-free survival (DFS) and OS in patients treated with standard 
induction and consolidation chemotherapy (Bloomfield et al., 1998, Grimwade et al., 
1998, Cho et al., 2003, Dohner et al., 2010). The morphological features include the 
presence of blasts with abundant basophilic cytoplasm containing in most of the 
cases, numerous azurophilic granules and blasts with characteristic Auer rods (Arber 
et al., 2003)..  
In addition, the leukemic blasts frequently have a distinct immunophenotype, 
characterized by the expression of myeloid markers (CD13, CD33, MPO), and also 
by the co-expression of the lymphoid marker CD19. CD34 is characteristically 
present, and CD56 is often expressed (Arber et al., 1997, Zheng et al., 2008, De et 
al., 2007). 
 
1.3.2 Biology of RUNX1-RUNX1T1 chimeric transcription factor 
More than 3 decades age the specific morphology associated with the t(8;21) 
translocation was defined and scientists came to an understanding of the genes 
involved (Rowley, 2000). 
The translocation t(8;21)(q22;q22) involves the AML1 gene (also known as RUNX1), 
located on chromosome 21, and the Eight-Twenty-One (ETO, MTG8 or RUNX1T1) 
gene, located on chromosome 8 (Chang et al., 1993, Erickson et al., 1992, Reikvam 
et al., 2011). According to the HGNC nomenclature RUNX1-RUNX1T1 is now the 
official name, although AML1-ETO is still common. It is responsible for the fusion of 
the N-terminal DNA-binding domain of the RUNX1 gene with almost the entire 
RUNX1T1 gene (including the region coding for the 4 C-terminal domains) (Erickson 
et al., 1992). RUNX1 is a key transcription factor for various hematopoietic specific 
genes. Less is known for the function of RUNX1T1, which is believed to be a nuclear 
co-repressor gene (Reikvam et al., 2011, Plevin et al., 2006).  
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RUNX1 or CBFA, is the DNA-binding subunit of the core-binding transcription factor 
(CBF). CBF is composed of two subunits CBFA and CBFB (Leroy et al., 2002). It 
binds to the enhancer core sequence TGT/GGT (Figure 2–Panel A), which has been 
shown to be important in the transcriptional regulation of a number of viral, and 
cellular genes (Wang et al., 1993). The DNA binding activity of RUNX1 is mediated 
through a central 118 amino acid domain that is homologous to the Drosophlila pair-
rule protein Runt, hence it is designated as the Runt homology domain (RHD) (Crute 
et al., 1996, Daga et al., 1996). This binding affinity is increased through 
heterodimerization of the RDH with a second non-DNA-binding subunit CBFB (Wang 
et al., 1993). RUNX1 has been shown to function as a transcription activator and it is 
of critical importance since it regulates the expression of the following haematopoietic 
specific genes: myeloperoxidase, granulocyte-colony-stimulating factor 1 (G-CSF) 
receptor, subunits of the T-cell antigen receptor, neutrophil elastase and the 
cytokines interleukin (IL) -3 and macrophage–colony-stimulating factor (M-CSF) 
receptor (Nuchprayoon et al., 1997, Zhang et al., 1994, Prosser et al., 1992, 
Shoemaker et al., 1990).  
 
Figure 2: The RUNX1 Transcription Factor 
 
 
Panel A: normal cells. Panel B: AML cells with t(8;21)                                                                                       
(Adapted from NEJM (Lowenberg et al., 1999)) 
 
 
B 
A 
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RUNX1T1 is the mammalian homologue of the Drosophila gene nervy (Feinstein et 
al., 1995) and contains four evolutionarily conserved domains, the so-called nervy 
homology regions (NHR) 1-4, which have been shown to interact with co-repressors 
and histone deacetylases (HDAC) (Amann et al., 2001). RUNX1T1 phosphoprotein is 
expressed in CD34+ haematopoietic progenitors (Era et al., 1995, Erickson et al., 
1996).  
In the RUNX1-RUNX1T1 fusion protein the transcriptional activation domains of 
RUNX1 are replaced by RUNX1T1 sequences known to interact with nuclear co-
repressors like N-CoR, SMRT and HDAC (Downing, 1999) (Fig 2- Panel B). 
Therefore, RUNX1-RUNX1T1 retains the ability to bind to the core enhancer 
sequence and to interact with CBFB. However, instead of activating transcription, it 
functions as a transcriptional repressor, inhibiting the normal transcriptional activity of 
the wildtype RUNX1-CBFB. RUNX1-RUNX1T1 targets the promoters of RUNX1 
target genes and directly represses RUNX1-mediated transcriptional activation 
(Meyers et al., 1995). It also represses CEBPA transcriptional activation (Westendorf 
et al., 1998) and the basal transcription of the multidrug resistance (MDR) gene 
(Lutterbach et al., 1998). Although the majority of data suggests that RUNX1-
RUNX1T1 functions as a transcriptional repressor, it has also been found to activate 
transcription of the BCL2 promoter (Klampfer et al., 1996). 
 
 
1.4 JAK-STAT signalling pathway and JAK2V617F mutation in Myeloid 
Disorders 
 
The Janus Kinase (JAK) / signal transducer and activator of transcription (STAT) 
cascade is an intracellular signalling pathway required for response to many 
extracellular ligands. It is widely used by members of the cytokine receptor 
superfamily, including receptors that are important in haematopoiesis (granulocyte 
colony-stimulating factor, erythropoietin, thrombopoietin, interferons and interleukins) 
(Yamaoka et al., 2004, Ward et al., 2000). 
Four cytoplasmic tyrosine kinases (JAK1, JAK2, JAK3 and TYK2) and seven STAT 
proteins (STAT1 to 6, including STAT5a and STAT5b) have been identified in 
mammalian cells (Ward et al., 2000). 
JAKs consist of seven regions of homology (JH) domains named Janus homology 
domain 1 to 7 (Becker et al., 1998, Chen et al., 1998, Schindler, 2002) (Fig 3 
(Schindler, 2002)). The C-terminal domain (JH1) contains the tyrosine kinase 
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function and is preceded by a pseudokinase domain (JH2). Its sequence shows high 
homology to functional kinases, but it does not possess any catalytic activity (Wilks et 
al., 1991). The N-terminal portion of the JAKs (spanning JH7 to JH3) is important for 
the receptor association and the non-catalytic activity (Frank et al., 1994). 
STATs consist of five domains which include: an amino-terminal domain (NH2), a 
coiled-coil domain, the DNA binding domain, a linker domain, an SH2 domain, and a 
tyrosine kinase domain (P) (Schindler, 2002). In the carboxy-terminus there is a 
transcriptional activation domain (TAD) which is conserved in function (between 
homologues), but not in sequence (Becker et al., 1998, Chen et al., 1998) (Figure 3 
(Schindler, 2002)).    
 
Figure 3: STAT and JAK structure 
 
(adapted from: J Clin Invest (Schindler, 2002)) 
 
The JAK-STAT signalling pathway is activated after binding of the specific cytokine 
with the receptor. This leads to the phosphorylation of specific receptor tyrosine 
residues (Schindler, 2002). As a result, STAT binds to the phosphorylated receptor 
and becomes also phosphorylated. After that the activated STAT protein is released 
from the receptor, it dimerizes and finally is transported into the cell nucleus to 
activate transcription of target genes (Fig 4 (Shuai and Liu, 2003)). Now JAK-STAT 
mediated signal transduction is known to regulates many cellular processes through 
the signalling of cytokines (Schindler, 2002).  
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Figure 4: JAK2-STAT5 signaling pathway 
 
 
(Adapted from Nat Rev Immunol. (Shuai and Liu, 2003)) 
 
 
In 2005 a novel somatic point mutation in the autoinhibitory domain of the JAK2 was 
described (Baxter et al., 2005, James et al., 2005, Levine et al., 2005, Zhao et al., 
2005, Kralovics et al., 2005). The mutation is referred to as V617F. It is the result of 
the substitution of valine from phenylalanine, at position 617 of the JAK2 protein, 
within the JH2 pseudokinase domain, which is involved in the inhibition of kinase 
activity. Loss of JAK2 autoinhibition results in uncontrolled activation of the kinase, 
thus cell proliferation becomes independent of the control of the normal growth factor. 
The mutation is very common in chronic myeloproliferative neoplasms (MPNs). It is 
detected in about 95% of patients with polycythemia vera (PV) (Tefferi, 2007) and in 
35-50% of patients with essential thrombocythemia (ET), or myelofibrosis with 
myeloid metaplasia (MMM) (Kralovics et al., 2005, Baxter et al., 2005, Levine et al., 
2005, Nelson and Steensma, 2006). The prevalence of JAK2V617F seems to be low 
in myelodysplastic syndrome (MDS) (about 7%) (Steensma et al., 2005) and in 
atypical mylodysplastic/myeloproliferative disorders (Steensma et al., 2006). In de 
novo AML the incidence of the mutation is approximately 4%-6% (Steensma et al., 
2005, Dohner et al., 2006), but it should be mentioned that in about 20-25% of AML 
patients has been reported increase activity of STAT3 (Steensma et al., 2006).  
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1.5 Monitoring of minimal residual disease in acute myeloid leukemia 
 
1.5.1 General aspects of minimal residual disease 
AML is a heterogeneous disease, as reflected by differences in the morphology of 
the leukemic blasts and by variations in the clinical picture and therapeutic outcome. 
Over the past 30 years, remarkable progress was made in understanding the biology 
of haematological malignancies and consequently new treatment modalities became 
feasible. Thus, with the contemporary improved risk assessment, chemotherapy, 
haematopoietic stem cell transplantation (HSCT) and supportive care, complete 
remission (CR) rates as high as 50% to 80% can be achieved (Mayer et al., 1994, 
Paietta, 2012) in adult patients with AML. However, despite this success half of the 
patients will eventually relapse due to the persistence of residual malignant cells 
surviving after chemotherapy. The persistence of residual malignant cells below the 
threshold of conventional morphological findings is termed minimal residual disease 
(MRD) and may identify patients at a higher risk of relapse (Venditti et al., 2000, 
Buccisano et al., 2009, Lane et al., 2008).  
In this setting, the aim of monitoring MRD is very important for:  
 monitoring the effectiveness of treatment in order to give individual 
information on disease prognosis and to design patient adapted post-
remission therapies. Especially for the group of “standard risk” 
patients, who are experiencing great heterogeneity in treatment 
response,   
 identification of cases with a high risk of relapse that then can be 
treated earlier and more effectively, 
 determining patients who will benefit from bone marrow 
transplantation (BMT), 
 assessing the effectiveness of new treatments. 
Hence, detection of low levels of malignant cells with molecular techniques has 
become a key tool of contemporary haematological diagnostics. The final goal of 
detecting MRD is to obtain an early evaluation of the effectiveness of the treatment 
and possibly provide pre-emptive therapy, as it is currently applicable for APL 
(Grimwade and Tallman, 2011, Paietta, 2012, Hourigan and Karp, 2013). 
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1.5.2 Techniques for MRD assessment  
Since MRD means the presence of leukemic cells among normal cells, techniques 
used for MRD detection rely on finding leukemia-specific markers, which distinguish 
the leukemic blasts from the normal cells. Currently, specific translocation markers 
are available for approximately 25% of AML patients and these include fusion genes, 
like RUNX1-RUNX1T1 and PML-RARA (Bhatia et al., 2012). With the detection of 
gene mutations, such as NPM1 (Papadaki et al., 2009) this spectrum will widen. 
For this purpose various techniques have been developed, which differ in specificity 
of the markers used, as well as in the detection levels. Each method has relative 
advantages and disadvantages (Radich and Sievers, 2000), but some of them, like 
morphology of the cells and conventional cytogenetics, are limited by their low 
sensitivity. Cytomorphology is still a standard technique for identification of complete 
remission but the detection limit is 10-1-10-2. It is based on the assessment of 
morphology of bone marrow cells with the use of a light microscope (Toren et al., 
1996). Sensitive methods to detect MRD include the “classic” metaphase 
cytogenetics, cell cytometry studies and molecular genetic studies such as 
polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH). 
However, techniques other than PCR are inferior due to low sensitivity. The higher 
sensitivity of PCR enables detection of 1 leukemic cell among 10-5-10-6 normal cells 
(Willemse et al., 2002). PCR-based techniques allow the detection of leukemia-
specific gene rearrangements by identifying either leukemia specific translocations or 
clone-specific immunoglobulin heavy chain (IGH) gene and T-cell receptor (TCR) 
gene rearrangements. Therefore, nowadays detection of MRD by PCR has become 
an essential tool for molecular monitoring of AML (Geng et al., 2012, Jourdan et al., 
2013, Paietta, 2012) and it can be quantified by the use of Reverse-Transcriptase 
PCR (RT-PCR) or the nested-PCR and quantitative PCR: Real time Quantitative 
PCR (RQ-PCR). MRD quantification can be carried out either by the end point 
(competitive) RT-PCR or the cycle-cycle (real-time) techniques.  
RQ-PCR can be used for MRD detection in the following cases: 
 detection of fusion genes like RUNX1-RUNX1T1, CBFB-MYH11 and PML-
RARA  
 detection of mutations of specific genes like NPM1, 
 detection of genes which are pathologically expressed like Wilms tumor (WT1) 
gene and Ecotropic viral integration-1 (EVI1) gene. 
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2. AIM OF THE STUDY 
 
 
AML is a disease with wide clinical and biological diversity. During the last decade 
much progress has been made in understanding the molecular and cytogenetic basis 
of acute leukemia. This complexity of the genetic findings has been taken into 
account in the last published WHO classification of AML (Vardiman et al., 2009). 
AML with t(8;21) belongs to the CBF leukemias and is associated with a favourable 
prognosis. However, despite the improved rates of CR, between 25% and 30% of 
patients will relapse with current treatment protocols (Yin et al., 2012, Leroy et al., 
2005). Therefore, identifying patients at a higher risk of relapse and thus preventing it, 
is of major clinical importance. Several studies (Leroy et al., 2005, Paietta, 2012, Zhu 
et al., 2013, Yin et al., 2012, Schnittger et al., 2003) have suggested that the 
molecular detection of residual leukemic blasts below the threshold of conventional 
morphological findings for CR (<5% blasts in the bone marrow), might be the most 
suitable method for the successful identification and prevention of relapse.  
The aim of this study is to establish a real time PCR assay for sensitive and specific 
RUNX1-RUNX1T1 quantification in relation to the Abelson gene (ABL1) as a 
reference housekeeping gene, which is suitable for monitoring MRD in routine 
diagnostics. Furthermore based on the finding that coexistence of JAK2V617F and 
RUNX1-RUNX1T1 mutation has a frequency of approximately 4%-6% in de novo 
AML (Steensma et al., 2005, Dohner et al., 2006), the presence of additional 
JAK2V617F mutation was examined in the sample material of the study using DNA 
melting curve analysis. 
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3. MATERIALS AND METHODS  
 
3.1   Material 
 
3.1.1   Oligonucleotides 
The oligonucleotides were purchased from Metabion (Munich). 
 
RUNX1-RUNX1T1 RQ-PCR  
RUNX1-RUNX1T1 primers and probes:  
 Forward primer: 5'-CACCTACCACAGAGCCATCAAA-3'   
Reverse primer: 5'-ATCCACAGGTGAGTCTGGCATT-3'  
TaqMan probe: 5'-6-FAM-AACCTCGAAATCGTACTGAGAAGCACTCCA-BHQ1-3' 
 
ABL1 primers and probes: 
Forward primer: 5'-CCTTTTCGTTGCACTGTATGATTT-3' 
Reverse primer: 5'-GCCTAAGACCCGGAGCTTTT-3' 
TaqMan probe: 5'-6-FAM-TGGCCAGTGGAGATAACACTCTAAGCATAACTAA 
 AGG-BHQ1-3' 
 
RUNX1-RUNX1T1 primary and nested PCR   
RUNX1-RUNX1T1 primers 
Primary    PCR 
AMLex: 5’-GAGGGAAAAGCTTCACTCTG-3’ 
ETOex: 5’-TCGGGTGAAATGTCATTGCG-3’ 
Nested PCR 
AMLint: 5’-GCCACCTACCACAGAGCCATCAAA-3’ 
ETOint: 5’-GTGCCATTAGTTAACGTTGTCGGT-3’ 
 
ABL1 primers 
Forward primer: 5’-GGCCAGTAGCATCTGACTTTG 
Reverse primer: 3’-ATGGTACCAGGAGTGTTTCTCC 
 
Melting curve analysis for JAK2V617F 
Forward primer: 5'- AAGCAGCAAGTATGATGAG-3' 
Reverse primer: 5'- CCCATGCCAACTGTTTAG-3' 
  
Hybridization Probes: 
JAK2-A: 5'-AGTGATCCAAATTTTACAAACTCCTGAACCAGAA-FL-3' 
JAK2-S: 5'-LC-Red-640-TTCTCGTCTCCACAGACACAT-P-3' 
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3.1.2   Mammalian cell lines  
In this work we used Kasumi-1 cell line (Human acute myeloid leukemia, Source: 
ACC220, DSMZ, Braunschweig, Germany), in order to establish a PCR method for 
the quantification of the RUNX1-RUNX1T1 transcripts. The cell line was used for the 
establishment of standard curves and as a positive control.  
Kasumi-1 is a cell line that was isolated in 1989 from the PB of a 7 years-old 
Japanese boy with AML (AML FAB M2). These cells carry the t(8;21) translocation 
that leads to the formation of RUNX1-RUNX1T1 fusion gene.   
The following cell lines were used as negative controls:  
1) K562, established from a patient with chronic myelogenous leukemia (CML) in 
blast crisis,  
2) ME1, derived from patient with AML (AML FAB M4Eo),  
3) NB-4, derived from patient with APL,  
4) OCI, derived from patient with acute myelomonocytic leukemia and  
5) SD1, derived from the PB of a patient with BCR-ABL positive acute lymphoblastic 
leukemia (ALL).  
 
3.1.3 Patients 
Patient samples were referred to the Laboratory for Leukemia Diagnostics, 
Department of Medicine III, Klinikum Großhadern, Munich, for routine cytogenetic 
and molecular analysis. Based on available sample material, we used BM samples 
from 37 AML patients and PB samples from 2 AML patients, from the cohort of 
AMLCG99 study population which were diagnosed positive for the RUNX1-RUNX1T1 
fusion gene encoded by translocation t(8;21)(q22;q22). The diagnosis was 
established in the Laboratory for Leukemia Diagnostics using molecular and 
cytogenetic analysis. 29 RUNX1-RUNX1T1 positive samples were available at 
diagnosis, 12 samples at day 16 of the induction therapy, 143 at various points 
during follow up and finally 5 RUNX1-RUNX1T1 positive samples at relapse. 
Diagnosis of AML was made morphologically and cytochemically as it has been 
previously described (Kern et al., 2003) and was based on FAB classification. All 
patients had been treated according to the therapeutic AMLCG99 protocol (Buchner 
et al., 1999, Buchner et al., 2003, Buchner et al., 2006). All patients had given their 
informed consent before entering the study. Table 4 and Table 5 provide the clinical 
and cytogenetic data of the patients included in the study at the time of diagnosis. As 
described in Table 6, in addition to the mutations that had already been studied, we 
also screened our RUNX1-RUNX1T1 positive patients for the detection of 
JAK2V617F mutation using melting curve analysis. 
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Table 4: Patients’ characteristics (n=39). 
Age (years)  
Range 
Median 
15.8-74.8 
45.92 
WBCsx103/µl  
Range 
Median 
0.98-50.610 
10.500 
PLTx103/µl  
Range 
Median 
4-273 
29 
Blasts at diagnosis (n=37)   
Range 
Median 
25-95% 
75% 
FAB subtype 
M1 
M2 
 
2 
37 
Abbreviations: FAB, French-American-British classification; PLT, platelet count; WBCs, white 
blood cells 
 
Table 5: Cytogenetics at diagnosis.  
Cytogenetics  Number 
Sole t(8;21) 11 
Loss of X or Y  19 
Del(9)(q22) 3 
Additional aberrations  6 
 
Table 6: Additional mutations  
FLT3-ITD  MLL-PTD  
+ 2 + 0 
- 
Not done 
36 
1 
 
- 39 
 
 
FLT3-D835  KIT- D816  
+ 1 + 5 
- 36 - 31 
Not done 2 Not done 3 
 
  JAK2V617F  
  + 0 
  - 
Not done 
18 
21 
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3.1.4 Chemicals and Kits  
Cell culture 
RPMI 1640 medium  (PANBiotech, Aidenbach) 
Fetal calf serum 10% (FCS )                           (Biochrom AG, seromed, Berlin) 
Penicillin/Streptomycin                                         (GIBCO, Germany) 
PBMCs cell separation 
Phosphate Buffer Saline (PBS)  (Dulbecco Biochrom AG, Berlin)  
Biocoll separating solution  (Biochrom AG, Berlin) 
Quicklyser-II  (Sysmex, Norderstedt) 
RNA isolation  
RLT buffer (Qiagen, Hilden) 
QIAshredder (Qiagen, Hilden) 
MagNA Pure LC mRNA Isolation KIT  (Roche, Mannheim) 
cDNA Synthesis  
Desoxynucleotide (dNTP’s)                                      (Invitrogen, Karlsruhe) 
dNTPs-Mix (10 mM)                                                             (Promega, Mannheim) 
Random hexamers primers p(dN)6      (Roche Diagnostics Mannheim) 
RNase Inhibitor  (Promega, Mannheim) 
Superscript II (Reverse Transcriptase)  (Invitrogen, Karlsruhe) 
Gel electrophoresis   
Agarose  (UltraPure, Invitrogen) 
DNA molecular weight marker VI  (Roche Diagnostics, Mannheim) 
Ethidium bromide 1% (10 mg/ml) (Carl Roth, Karlsruhe) 
Loading dye 6x  (Promega, Mannheim) 
10x TBE buffer (Roche, Mannheim) 
PCR  
Taq polymeRASe  (Qiagen, Hilden) 
dNTPs (Invitrogen, Karlsruhe) 
LightCycler TaqMan Master Mix (Roche Diagnostics, Mannheim) 
LightCycler Fast Start DNA Master HybProbe (Roche Diagnostics, Mannheim) 
Kits   
MagNA Pure LC mRNA Isolation KIT  (Roche, Mannheim) 
LightCycler TaqMan Master Mix (Roche Diagnostics, Mannheim) 
LightCycler Fast Start DNA Master HybProbe (Roche Diagnostics, Mannheim) 
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3.1.5 Laboratory equipment  
Cell culture incubator (WTB, Tuttlingen) 
Centrifuger Rotanta 460R  (Hettich, Germany) 
Cell culture CO2 incubator  (Heraus, Osterode) 
Eppendorf centrifuge 5415D  (Eppendorf,Hamburg) 
Eppendorf cups (0.5-1.5 ml)  (Eppendorf, Hamburg) 
Eppendorf® tabltop centrifuge 5415D (Eppendorf, Hamburg) 
Electrophoresis champer (Horizon 11-14, GIBCO BRL, USA) 
Falcon tubes® (Becton Dickinson,  Biosciences) 
Fridge (4°C, -20°C)  (Siemens AG, Erlangen) 
Fridge (-80°C) UF80-450S (Colora Messtechnik GmBH, Lorch)  
Gel electrophoresis systems (Bio-rad, Munich) 
LightCyclerTM real-time PCR machine  (Roche Diagnostics, Mannheim) 
MagNA Pure LC  (Roche Diagnostics Mannheim) 
Microcell counter (Sysmex, Norderstedt) 
Pipette Accu-jet  (Brand, Wertheim) 
Pipette tips (Star Labs, Munich) 
Pipettes (Gilson, Langenfeld and Eppendorf, 
Hamburg) 
Pipettes, Tissue culture flasks, 
Centrifuge vials 
(Sarstedt, Nümbrecht) 
 
Thermocycler Cyclone 25 
Thermocycler T3  
(Peqlab Biotechologie, Erlagen) 
(Biometra) 
Vortex (Scientific industries Bohemia USA) 
 
3.1.6 Software 
Adobe Illustrator  (Adobe Systems, Unterschleißheim)  
Adobe Photoshop  (Adobe Systems, Unterschleißheim)  
EndNote 6.0.2  (Thompson ISI, Carlsbad, CA, USA)  
Microsoft Office 2003  (Microsoft, Redmond, WA, USA) 
SigmaPlot 6.0  (SPSS Incorporated, Chicago, USA)  
LightCycler SW Version 3.5 and 4.05 (Roche Diagnostics, Mannheim) 
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3.2 Methods 
 
3.2.1 Cell culture  
 
Cells were cultured in RPMI-1640 medium with 10% heat inactivated Fetal Bovine 
Serum (FBS) supplemented with 5 U/ml of penicillin and streptomycin at 37°C under 
a humid condition in 5% CO2.  
They were suspended in the medium to reach a final cell concentration of 1x106 
cells/ml. Every 2 or 3 days saturated cultures were divided at a ratio of 1:2 to 1:3. 
 
3.2.2 Isolation of PB mononuclear cells 
The isolation of peripheral blood mononuclear cells (PBMCs) was performed with 
gradient density centrifugation, using Biocoll separating solution. Ficoll has a higher 
density than lymphocytes or monocytes and a lower density than erythrocytes and 
granulocytes. By centrifugation, monocytes, lymphocytes and natural killer cells 
(PBMCs) are enriched in the interphase layer between whole blood/bone-marrow 
and the Ficoll solution and can be recovered by pipetting.  
15 ml of Biocoll separating solution (density = 1.077 at +20°C) was placed in 50 ml 
centrifuge tubes. 5-10 ml of heparinized BM or whole blood were mixed with an equal 
volume of phosphate buffer saline (PBS) in 50 ml centrifuge tubes and then were 
applied over Biocoll separating solution using a sterile 10 ml pipette, with caution. 
Centrifugation at 1200 g (without brake) for 20 min at room temperature was followed. 
The layer of mononuclear cells, formed between the aqueous face and the Ficoll was 
collected using a 10 ml disposable pipette. The cells were then carefully transferred 
to a 50 ml vessel and washed with 1xPBS. The supernatant after a 10 min 
centrifugation at 300 g was discarded. Cell counting was performed using the 
Microcell counter. Aliquots of 10x106 cells (samples during diagnosis and follow up) 
were then prepared and immediately lysed in 300 µl of RLT buffer. The RLT lysates 
were stored in 1.5 ml centrifuge tubes at -80°C.  
 
3.2.3 RNA extraction  
3.2.3.1   RNA extraction from patient samples 
RNA isolation from PBMCs was manually performed using the MagNA Pure LC 
mRNA isolation KIT, according to the manufacturer protocol with minor modifications. 
In brief, the RLT lysates were initially thawed at room temperature. The cells were 
washed twice with ice cold PBS, RLT lysis buffer (250 μL) was added to the cell 
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pellet and homogenization was performed using QIAshredder. RNA was extracted 
using MagNa Pure Nucleic Acid Purification System, according to the manufacturer’s 
instructions. Final elution of mRNA was performed in a volume of 30 μl.  
RNAse free disposables (test tubes and pipette tips) were used during processing 
RNA. 
 3.2.3.2   RNA extraction from Kasumi-1 cell line  
3x106 Kasumi-1 cells were lysed in 300 μl RLT buffer. mRNA extraction was carried 
out using the same protocol as described for the patients samples.  
 
3.2.4   cDNA synthesis 
Isolated mRNA was reversely transcribed to complementary DNA (cDNA) using 
Superscript II reverse transcriptase (Invitrogen Karlsruhe, Germany).  
10 μL of mRNA extracted from Kasumi-1 cell line and/or from samples at diagnosis 
were used in the reverse transcription (RT) reaction.  
For MRD detection cDNA synthesis was performed using 30 μL of mRNA, extracted 
from approximately 10x106 cells.   
RNA samples were initially denatured in 70oC for 8 min and then cooled down to 4oC 
prior to adding the RT Mastermix in a final volume of 50 μl.  
RT MasterMix was prepared as follows: 
 
Table7: RT-MasterMix 
MasterMix cDNA synthesis Volume  
5x First-Strand Buffer  
dNTPs (10 pmol/μl) 
10.0 μl  
4.4 μl  
Random Primer (50 μg/μl) 2.5 µl    
RNasin (40 U/μl) 1.25 μl   
SuperScript II RT (200 U/μl) 1.9 µl  
RNase-free water  up to 20 or 40 µl 
 
MasterMix was then added to each RNA sample and RT was performed at 37oC for 
60 min. The reaction was stopped by heat inactivation of the enzyme at 95 oC for 5 
min.  
ABL1 gene amplification was performed for each sample in order to control the RNA 
integrity (Schoch et al., 2002). Strict precautions were taken in order to prevent cross 
contamination. As negative control RNA derived from RUNX1-RUNX1T1 negative 
cell lines was used (paragraph 3.1.2) RNAse-free water was also used as a non-
template control. Finally, amplification products were analysed on 2% agarose gels 
stained with ethidium bromide. 
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3.3 Principle of PCR  
PCR is the most sensitive and widely used technique in MRD detection. It was first 
described in the mid-1980s by Kary B. Mullis (Mullis and Faloona, 1987). The 
technique is based on the enzymatic amplification of a DNA fragment that is bounded 
by two primers. Primers are oligonucleotides that are complementary to the target 
sequence and bind specifically to it. The DNA portion bounded by the two primers is 
used as a template for the construction of the complementary strand.  
The reaction requires deoxynucleotide triphosphates (dNTPs) which are used to 
create the cDNA strand and is catalysed by a thermostable DNA polymerase, (Taq 
polymerase, of the species Thermus aquaticus). For RNA quantification, RT takes 
place as a first step before PCR, in order to convert RNA into cDNA. The cDNA can 
be stored for a long time. It is commonly accepted that RNA is extremely unstable 
(compared to DNA). Thus collection, storage and transport of the samples have to 
take place with great caution to avoid contamination and to ensure the integrity of the 
samples (Valasek and Repa, 2005). 
PCR is a chain reaction of repeated cycles, with each cycle consisting of three steps: 
denaturation of double strand DNA at about 950C, primer annealing at about 630C 
(depending on the primer sequence) and extension/elongation step, where synthesis 
of the new strand occurs at 720C. After 20 cycles, roughly 1 million copies of the 
target DNA sequence are produced. After a number of cycles the exponential phase 
reaches the plateau phase due to accumulation of end-product inhibitors or depletion 
of the substrates. The detection of the PCR products at the plateau phase of the 
PCR reaction (end-point detection) cannot lead to a correlation between the amount 
of PCR product and the DNA quantity used as a template in the PCR reaction. The 
first attempts for quantifying the DNA template were based on end-point analysis 
(competitive PCR). 
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Figure 5 : Principle of PCR 
 
(adapted from Roche Applied Science Technical Note No. LC 10/update 2003) 
 
  
3.3.1 Principle of real-time PCR  
Real-time PCR offers an alternative method for both qualitative and quantitative 
analysis. The principle of this technique is to estimate the levels of PCR products as 
these accumulate at the exponential phase of the amplification, rather than 
estimating the level of the final products (competitive RT-PCR). The detection of the 
product depends on the fluorescent signals which are produced during the reaction. 
In the quantitative RT-PCR the fluorescent signal measured at each amplification 
cycle is correlated to the amount of PCR product formed, and finally is converted into 
a numerical value for each sample.  
In this study, RQ-PCR was performed using LightCycler instrument 1.5. In this 
apparatus, PCR occurs in special glass capillaries which are placed into a carousel, 
and air is used for fast heating and cooling (Wittwer et al., 1997). A micro-volume 
fluorimeter is used to quantify the amplification products and the whole reaction is 
recorded in the screen of the connected PC and analysed using the appropriate 
software.  
The fluorescent signal increases exponentially during the amplification phase of the 
PCR reaction. In the amplification reaction, the cycle at which the fluorescence of the 
sample rises above the background is called the Crossing Point (CP) (which is 
usually determined at the first 3-15 cycles of the reaction). Quantification in real-time 
PCR involves the determination of the CP of a sample. 
 
  Materials and methods 
 
 
32 
 
           3.3.1.1   Detection of the PCR products 
The fluorescent signal can be produced using different assay methods: 
i) Sequence-independent detection assays (typically SYBR Green I) and 
ii) Sequence-specific probe binding assays (hydrolysis probes, 
hybridization probes). 
The LightCycler offers several formats for detection of the PCR products, including 
hydrolysis or TaqMan probes, which were applied in this work. This probe is an 
oligonucleotide with a reporter dye attached at the 5’ end and a quencher dye at the 
3’ end. As long as the probe is intact, the fluorescent dyes are close to each other 
and the signal produced from the reporter dye is “suppressed” by the quencher dye. 
The fluorescent quenching is due to Fluorescence Resonance Energy Transfer 
(FRET) (Clegg, 1995).  
The hydrolysis probes emit fluorescence when 5’-3’ exonuclease activity of Taq 
polymerase degrades the TaqMan probe. In this way reporter and quencher are 
separated and fluorescent dye is released. The amount of the PCR product is directly 
proportional to the increase of the fluorescence of the reporter dye measured. Figure 
6 shows schematically the principle of hydrolysis probes. As mentioned above 
TaqMan probes are cleaved during the PCR assay, so they cannot be used to 
perform melting curve analysis (Wittwer et al., 1997, Bustin, 2000). 
 
Figure 6: Principle of hydrolysis 
 
(adapted from Roche Applied Science Technical Note  No. LC 18/2004) 
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3.3.2 Relative quantification using LightCycler technology 
Relative quantification is defined as the ratio of target DNA to a reference gene 
(housekeeping gene). The reference gene is a gene that is expressed constitutively 
at the same level in all samples analysed. 
 
 
3.3.2.1   Relative quantification calibrator normalized 
In this method, the absolute value of CP is used in order to calculate the normalized 
value of the amount of the target gene in relation to a calibrator. At first, the CP 
difference (ΔCP) between the housekeeping and the target gene is calculated for 
both, the sample and the calibrator (ΔΔCP= ΔCP sample -  ΔCPcalibrator ). Finally based on 
the equation 2-ΔΔCP the normalized value of the target gene in relation to the calibrator 
is calculated.   
 3.3.2.2   Relative quantification with external standards  
Serial dilutions of DNA standards for reference and target genes are used to create 
standard curves. Sample and calibrator CP values are analysed using the 
corresponding standard curve in order to be quantified.     
Then the target gene is normalized to the reference gene, by dividing the amount of 
the target gene to the amount of the housekeeping gene.  
 
The two genes cannot be amplified with the same efficiency, since PCR efficiency is 
influenced by target-specific factors, such as primer annealing, GC-content and 
product size. The optimum PCR efficiency is 2 (E=2) which means that the amount of 
PCR product duplicates during each cycle. This corresponds to a slope of -3.32 of 
the standard curve. The slope of that curve can be directly converted into efficiency 
using the formula: E = 10–1/slope. 
 
 
=    Relative ratio 
target gene concentration 
Reference gene concentration 
Calibrator - 
normalized ratio  
Ratio   target / reference (sample)  
Ratio   target / reference (calibrator)  
 = 
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Figure 7: Principle of relative quantification with external standards 
 
(adapted from Roche Applied Science Technical Note No L.C 10/update 2003) 
 
In order to create standard curves for the reference and the target gene, serial 
dilutions of cDNA from Kasumi-1 cell line was used. All samples were assayed in 
duplicates. In all experiments Kasumi-1 cell line was used as a positive control, 
RUNX1-RUNX1T1 negative cell line as negative control and RNAse-free water as a 
non template control. Results were analysed using the LightCycler SW4.5. The RQ-
PCR reaction was carried out in a total volume of 20 μl per capillary. The MasterMix 
was prepared as follows: 
 
Table 8 : RQ-PCR reaction mix 
MasterMix PCR Concentration Volume/capillary 
RNAse free H2O  11.6 μl 
Probe 10 μΜ 0.2 μΜ 0.4 μl 
Forward primer 10 μΜ 0.5 μΜ 1 μl 
Reverse primer 10 μΜ 0.5 μΜ 1 μl 
LC TaqMan Master Mix 1x 4 μl 
Volume  18 μl 
cDNA  2 μl 
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RQ-PCR for RUNX1-RUNX1T1 was performed in the LightCycler using the following 
conditions: 
 
Table 9: RQ-PCR protocol  
Analysis 
mode 
Cycles Segment Target 
Temperature 
Hold 
Time 
Acquisiti
on Mode 
Pre-Incubation 
None 1  95oC 10 min none 
Amplification 
Quantification 50 Denaturation 95 oC 10 s none 
  Annealing 63 oC 30 s none 
  Extension 72 oC 01 s single 
Cooling 
None 1  40 oC 30 s none 
 
The analysis was displayed in the fluorescent channels F1/F3 (530/705 nm).  
 
 
3.3.3 Qualitative primary/nested PCR for the detection of the RUNX1-
RUNX1T1 hybrid gene 
To perform primary and nested PCR reaction (qualitative PCR), 1, 5, and 10 μl of 
cDNA, that was transcribed as described in paragraph 3.2.4, was used.  
The primary PCR reaction was performed in a final volume of 50 μl containing 0.5 μM 
of each primer under the cycling conditions described in Table 10. Primers’ 
sequences were described previously (Miyamoto et al., 1997) and are shown on 
page 23. 5 and 10µl of the first PCR product were used as a template for the nested 
PCR reaction using nested primers as listed on page 23. Cycling conditions were the 
same as for the primary PCR reaction. Each PCR reaction contained a positive 
control from Kasumi-1 cell line and RNAse-free water as a non template control. 
The sensitivity of the primary and the nested PCR was assessed using ten-fold cDNA 
dilutions from the Kasumi-1 cell line. Established guidelines to prevent PCR 
contamination were stringently followed. 
ABL1 amplification was used to check RNA integrity in all patient samples. Following 
the guidelines given by the Europe Against Cancer (EAC) program (Beillard et al., 
2003), ABL1 was used as a reference gene, since it is constantly expressed in all 
investigated samples. Importantly ABL1 gene doesn’t contain any pseudogene. 
All patient samples were tested in duplicate.  
Primers are listed in paragraph 3.1.1 (page 23).  
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Table10:. Conditions of the primary and nested PCR for RUNX1-RUNX1T1 and ABL1 .  
PCR program  
94oC 5 min 
94oC 60 sec 
62oC 60 sec            35 cycles 
72oC 60 sec 
72oC 10 min 
 
 
3.4 Melting curve analysis  
 
3.4.1 Principle of melting curve analysis 
The melting temperature (Tm), is the temperature at which 50% of the DNA becomes 
single stranded. Tm is specific for each double-stranded DNA (ds DNA) because it is 
primarily dependant: a) on the length of the dsDNA, b) the degree of the GC content 
(Tm is higher in GC-rich fragments) and c) on the degree of complementarity 
between the strands. This is why melting curve analysis is able to distinguish PCR 
products with the same length but different GC/AT ratio. Therefore, the method can 
be applied for mutation analysis, such as point mutations or small deletions.  
In melting curve analysis, hybridization probes can be used. Hybridization probes are 
two specifically designed, sequence-specific oligonucleotide probes, labelled with 
different dyes. After hybridization, in the annealing phase, these probes are designed 
to bind to the amplified DNA fragment in a head-to-tail orientation, bringing the two 
dyes into close proximity. Consequently, the emitted energy excites the acceptor dye 
attached to the second hybridization probe, which then emits fluorescent light at a 
different wavelength.  
In mutation analysis, a pair of hybridization probes, complementary to the wild-type 
sequence, is used. In cases where mutant sequence is amplified the probe binds to 
the DNA with a mismatch, which results in a 5oC decrease of the Tm.  
After PCR amplification, the hybridized products are slowly heated with continuous 
measurement of the fluorescent signal until the point that the probes are not in close 
proximity anymore and the fluorescent signal decreases. The “mutation” probe 
dissociates at a different temperature and the melting point is shifted. That means 
that every mutation has its own melting curve. If there is only one mutant allele, the 
melting curve shows two peaks, one corresponding to the mutant allele and the other 
to the wild type. 
 
  Materials and methods 
 
 
37 
 
3.4.2 Melting curve analysis for the detection of the JAK2 gene mutation 
(V617F) 
Screening of RUNX1-RUNX1T1 positive patients for the presence of JAK2V617F 
mutation was performed using melting curve analysis, on the LightCycler instrument 
1.5 (Roche Diagnostics, Mannheim, Germany) and the results were analyzed with 
LightCycler SW 4.5. Sequences of primers and probes are shown in paragraph 3.1.1 
(page 23). The PCR reaction MasterMix is listed in Table 11 and the cycling 
conditions for the melting curve analysis are presented in Table 12.   
 
Table 11: MasterMix for Melting curve analysis 
 
 
Table 12: Cycling conditions for Melting Curve analysis 
Analysis 
Mode 
Cycles Segment Target 
Temperature 
Hold 
Time 
Acquisition 
Mode 
Pre-Incubation 
None 1  95oC 10 min none 
Amplification 
Quantification 40 Denaturation 95oC 1 sec none 
  Annealing 60oC 10 sec single 
  Extension 72oC 10 sec none 
Melting Curve 
Melting curve 1  95oC 1 min none 
   40oC 20 sec none 
   85oC 0 sec continuous 
Cooling 
None 1  40oC 1 min none 
 
The analysis was displayed in the fluorescent channels F2/F1 (640/530 nm) 
(Schnittger et al., 2006a).  
MasterMix Concentration Volume/capillary 
RNAse free H2O  9.6 μl 
MgCl2 4 mM 2.4 μl 
Hyb-probe S 0.75 μΜ 1 μl 
Hyb-probe A 0.75 μΜ 1 μl 
Left primer  0.5 μΜ 1 μl 
Right primer  0.5 μΜ 1 μl 
LightCycler-FastStart DNA Master 1x 2 μl 
MasterMix  18 μl 
cDNA  2 μl 
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3.5 Agarose gel electrophoresis 
 
2g of agarose powder were added to 100 ml of electrophoresis buffer (1xTBE) (2%) 
and then the mix was heated in a microwave oven until agarose dissolved. After the 
cooling of the solution to 50oC, 3.5 μl ethidium bromide (0.35 μg/ml) was added and 
the warm solution was poured into a tray and let to cool in room temperature for 30-
40 minutes. Then the gel was placed in an electrophoresis chamber and covered 
with 1xTBE buffer. 5 μl of loading dye was added to 20 μl of PCR product and placed 
into the well. A DNA molecular weight marker (0.15-2.1 kbp) was used as a ladder for 
size reference and the agarose gel electrophoresis was run at 140 Volts for 
approximately 40 min, then the gel was visualized and photographed under UV light.  
Primary and nested PCR products were separated and visualized after agarose gel 
electrophoresis. 
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4. RESULTS 
 
4.1   Positive control 
 
As a RUNX1-RUNX1T1 positive control, the Kasumi-1 cell line was used. 10μL of 
mRNA extracted from approximately 106 cells of Kasumi-1 cell line were used for 
cDNA synthesis, as already described in the method section (3.2.4, page 29). 
Kasumi-1 cDNA concentration was pooled, aliquoted and frozen at a concentration of 
1771.0 ng/μl. For the establishment of the LightCycler-PCR assay and the 
preparation of the standard curves (target, reference gene), 10-fold serial dilutions of 
cDNA Kasumi-1 cell line were used. The dilutions were prepared in TE buffer (10 mM 
Tris, 1 mM EDTA, pH:7) as follows: 1:10, 1:100, 1:1000, 1:10000, 1:50000, 1:100000 
and 1:1000000. In PCR, 10 μl of the 10fold dilution of the Kasumi-1 cDNA in TE were 
used. 
 
 
4.2   Establishment of the Real-time Quantitative PCR for RUNX1-
RUNX1T1 quantification 
 
4.2.1   Relative quantification – Reference gene 
The principle of relative quantification has been described in the section 3.3.2 (page 
33). To create the assay, and to compensate variations of RNA amount and integrity, 
RUNX1-RUNX1T1 fusion transcript was normalized to a reference gene, the 
housekeeping gene ABL1. ABL1 was chosen according to “Europe Against Cancer 
(EAC) Program” (Gabert et al., 2003).  
 
 
Relative ratio =  
 
 
 
 
 
 
 
RUNX1-RUNX1T1  concentration 
ABL1  concentration 
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4.2.2   Calibrator 
To normalize sample values within a run and between runs, the RUNX1-
RUNX1T1/ABL1 expression ratios in all samples were divided by the RUNX1-
RUNX1T1/ABL1 expression ratio of a calibrator. cDNA of the Kasumi-1 cell line was 
used as a calibrator: 
 
Calibrator normalized ratio =  
 
 
4.2.3   Primers and Probes  
The oligonucleotides for RQ-PCR were designed using the Primer Express 2.0 
software (PE Applied Biosystems). 
In order to design primers and probes special guidelines were taken into 
consideration (Bustin, 2000). Primers and probes should have G/C content between 
30% to 80% and a balanced distribution of G/C and A/T bases rich domains. Probes 
should have a Tm that allows annealing at 5-10oC higher than the Tm of the primers. 
Length of Primers should be between 20-24 bp and length of TaqMan probes 30 bp 
according to recommendations in the Roche Applied Technical Note No. LC 
11/update 2003.  
The primers’ and probes’ sequences for the quantification of RUNX1-RUNX1T1 are 
in accordance to the “Europe Against Cancer Program” (Gabert et al., 2003) 
(GenBank Accession Numbers D43969 (AML1) and D14289 (ETO). Sequences are 
listed in paragraph 3.1.1 (page 23) and have the following characteristics:  
Forward primer: GC% = 50% and Tm = 60.3oC  
Reverse primer: GC% = 50% and Tm = 60.3oC  
TaqMan probe: GC% = 47% and Tm = 66.8oC   
ABL1 was the recommended housekeeping gene, according to the “Europe Against 
Cancer Program” (Gabert et al., 2003).  
GenBank Accession Number M14752 was used in order to design the primers and 
probe with the software mentioned above. 
Primers and probes for ABL1 have the following characteristics: 
Forward primer: GC% = 38% and Tm = 58oC  
Reverse primer: GC% = 55% and Tm = 58oC  
TaqMan probe: GC% = 43% and Tm = 70oC   
 
Ratio   RUNX1-RUNX1T1  /  ABL1 (sample) 
Ratio   RUNX1-RUNX1T1  /  ABL1 (calibrator) 
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4.2.4   Optimization of RQ-PCR protocol for RUNX1-RUNX1T1 
In order to set up and optimize the runs on the LightCycler, the LC Software Short 
Guide Version 3.3, April 2000 as well as the LC Operator΄s Manual Version 3.5, 
October 2000 were used. PCR conditions were optimized using cDNA from the 
Kasumi-1 cell line in order to achieve the highest possible efficiency, specificity and 
sensitivity.   
For example, annealing temperatures at 60, 61, 62, 63, 64, and 65oC and an 
annealing time range between 15 to 40 sec, were tested. The highest efficiency and 
specificity was achieved at 63oC and 30 sec, as it was shown by gel electrophoresis. 
The results were not specific when using lower annealing temperature or a shorter 
annealing time. The initial denaturation was performed at 95 oC for 10 min, followed 
by 50 amplification cycles of denaturation at 95 oC for 10 sec, annealing of the 
primers for 30 s at 63oC and extension at 72 oC for 1 sec. Finally, the reaction was 
cooled down to 40 oC for 30 sec. The final protocol of RQ-PCR, is also presented in 
Table 9, page 35. 
 
4.2.5   PCR protocol for amplification of the reference gene ABL1 
PCR reactions for the reference gene (ABL1) were carried out under the same 
conditions as described for the target gene (RUNX1-RUNX1T1). This represents an 
important advantage for routine diagnostics meaning that target and reference gene 
can be included in one run. 
 
4.2.6   Creation of the standard curves 
Standard curves for the target and reference gene were prepared separately by 
performing 10 fold dilutions (10-6 to 10-1) of cDNA from Kasumi-1 cells. 
To create a standard curve for RUNX1-RUNX1T1, the cDNA from Kasumi-1 cells 
were diluted as follows: 1:10, 1:100, 1:1000, 1:10000, 1:50000 and each of these 
dilutions were analyzed 2 to 6 times.  
To create the standard curve for the reference gene the following concentrations 
were used: 1:10, 1:100, 1:1000, and 1:10000. Each dilution was analyzed 6 times. 
Finally, a good linearity and reproducibility of the standard curve was obtained for 
both the RUNX1-RUNX1T1 and ABL1 assay (Fig 8). 
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Figure 8: Amplification plots of 10-fold dilutions of Kasumi-1 cell line cDNA: a) Target 
gene amplification curves b) reference gene amplification curves 
 
 
 
 
 
 
 
a. 
b. 
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Table 13: a) Median CP values of the standard curve target gene experiment  
Dilution of Kasumi-1 cDNA Median CP value 
1:10 25.3 
1:100 28.81 
1:1000 32.17 
1:10000 35.195 
1:50000 37.82 
 
                  b) Median cp values of the reference curve target gene experiment 
Dilution of Kasumi-1 cDNA Median CP value 
1:10 28.55 
1:100 32.01 
1:1000 35.36 
1:10000 38.73 
 
 
The CP differences between the average CP values of the 10fold dilutions 
theoretically should be 3.3 corresponding to a slope of the standard curve of -3.3 and 
to a maximum efficiency of 2.0 (van der Velden et al., 2003). CP values of target and 
reference curve are presented in Table 13. 
The efficiency (E) and the error (r) for the amplification of RUNX1-RUNX1T1 was 
1.999 and 0.0532 respectively (Fig 9a). For ABL1 amplification the efficiency and 
error was 1.973 and 0.0171 (Fig 9b). According to the manufacturer’s instructions 
(Roche Applied Science, Technical Note No LC 10/update 2003) the optimal 
efficiency is 2.0 and an error below 0.2 is acceptable (Fig 9). 
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Figure 9: Standard curves prepared from the data in figure 8 a) RUNX1-RUNX1T1 
standard curve: slope -3.3, E=1.999 and r= 0.0532. (b) Abl1 standard curve: slope -3.4, 
E=1.973 and r=0.017 
 
 
 
 
4.2.7 Reproducibility, sensitivity and specificity of the assay 
To determine the sensitivity of the assay, serial dilutions of cDNA from Kasumi-1 cell 
line were used as a template in RUNX1-RUNX1T1 and ABL1 RQ-PCR. In order to 
check the reproducibility of the assay each experiment was repeated 5 times. The 
maximum sensitivity for both assays was higher than 10-4 (5x10-4) (Table 14). 
Maximum sensitivity is defined as the lowest dilution step giving specific amplification. 
Additionally the experiment was repeated using a known concentration of cDNA from 
3 RUNX1-RUNX1T1 patients that was serially diluted (1:10-1:50000). The maximum 
sensitivity reached was higher than 10-4 (5x10-4) (Table 15). 
a) 
b) 
RUNX1-RUNX1T1 
ABL1 
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In order to determine the specificity of the assay, RUNX1-RUNX1T1 negative 
patients were tested; along with cDNA from K562, ME1, NB4, OCI, and SD1 cell line. 
No amplification was observed (data not shown). 
 
Table 14:  Median CP values of 5 repeated experiments to check the reproducibility and 
sensitivity of the assays  
 
a) Target gene  
Kasumi-1 cDNA 
Experiments 
I                       II                    III                  IV                   V 
Serial dilutions 
CP values 
 (Median) 
CP values 
 (Median) 
CP values 
 (Median) 
CP values 
 (Median) 
CP values 
 (Median) 
1:10 25.79 25.54 25.55 25.22 25.3 
1:100 29.67 29.5 29.52 28.75 28.81 
1:1000 33.01 33.11 33.15 32.03 32.17 
1:10000 36.24 36.44 35.69 35.31 35.19 
1:50000  40.09 39.32  37.82 
 
b) Reference gene 
Kasumi-1 cDNA 
Experiments 
I                       II                    III                  IV                   V 
Serial dilutions 
CP values 
 (Median) 
CP values 
 (Median) 
CP values 
 (Median) 
CP values 
 (Median) 
CP values 
 (Median) 
1:10 29.26 28.68 28.91 28.71 28.55 
1:100 32.40 32.01 32.22 32.11 32.01 
1:1000 35.71 35.49 35.92 35.81 35.36 
1:10000 38.74 39.19 38.9 38.52 38.73 
1:50000 39.54  40.0  38.99 
 
 
Table 15: Sensitivity of the assay using serial dilutions of known cDNA concentration 
from 3 RUNX1-RUNX1T1 positive patients  
 Patient 1 Patient 2 Patient 3 
Serial dilutions of 
cDNA 
CP values 
(Median) 
CP values 
(Median) 
CP values 
(Median) 
Kasumi-1 1:10 24.85 25.27 25.52 
 1:10 26.57 24.10 25.88 
 1:100 30.04 31.40 29.36 
 1:1000 33.69 33.50 32.89 
 1:10000 36.19 35.09 35.75 
 1:50000 37.54 37.57 38.25 
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Additionally 30 patient samples at various disease stages were amplified with RQ-
PCR and conventional PCR in order to further investigate the sensitivity and 
specificity of the assay. As shown in Table 16, 26 out of 30 samples were positive 
with RQ-PCR whereas only 24/30 were tested positive using 5 μl in the nested 
reaction. As expected 29/30 were positive using 10 μl in the nested reaction.  
 
Table 16: Patient samples (N=30) at various disease stages 
Patients RQ-PCR Primary RT-PCR Nested RT- PCR 
 CP values 
(Median) 
 5 μL 10 μL 
1 20.76 + + + 
2 26.67 + + + 
3 33.78 + + + 
4 35.62 + + + 
5 _ _ _ _ 
6 21.33 + + + 
7 24.33 + + + 
8 22.70 + + + 
9 26.67 + + + 
10 28.01 + + + 
11 30.74 + + + 
12 _ _ + + 
13 36.62 _ _ + 
14 _ _ + + 
15 26.13 _ + + 
16 26.71 _ _ + 
17 _ _ + + 
18 31.14 + + + 
19 21.79 + + + 
20 30.96 + + + 
21 25.32 + + + 
22 35.30 _ + + 
23 23.78 + + + 
24 38.69 _ _ + 
25 37.07 _ _ + 
26 36.82 _ + + 
27 30.05 _ + + 
28 31.16 _ + + 
29 35.96 _ + + 
30 37.34 _ _ + 
Positivity (%) 86.6% 50% 80% 96.6% 
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Thus the sensitivity of RQ-PCR was 100% when compared to RT-PCR with 1 μl of 
PCR product, 87.5 and 89.5% compared to RT-PCR using 5 and 10 μl of primary 
PCR product. The specificity of the assay was 26%, 16% and 100% respectively. 
(Table 17).  
Having established the assay, a total of 184 samples (39 patients) in diagnosis and 
during follow up (paragraph 3.1.3, page 24) were tested in parallel with conventional 
nested PCR (paragraph 4.3). 
 
Table 17: Sensitivity and specificity of RQ-PCR 
 “gold standard 1” 
RT-PCR 1μl 
 
Condition positive Condition negative 
True positive   = 15 False positive  = 11 
False negative = 0 True negative  = 4 
Sensitivity = 15/15=1=100% Specificity = 4/15=0.26=26% 
 
 “gold standard 2” 
RT-PCR 5μl * 
 
Condition positive Condition negative 
True positive   = 21 False positive  = 5 
False negative = 3 True negative  = 1 
Sensitivity = 21/24=0.875=87.5% Specificity = 1/6=0.166=16% 
 
 “gold standard 3” 
RT-PCR 10μl * 
 
Condition positive Condition negative 
True positive   = 26 False positive  = 0 
False negative = 3 True negative  = 1 
Sensitivity = 26/29=0.895=89.5% Specificity = 1/1=100% 
*nested reaction 
 
4.2.8  Evaluation of RQ-PCR data  
4.2.8.1   Data transfer in LightCycler Software 4.05 
Data were collected using the LightCycler Software 3.5 and were transferred into the 
LightCycler software 4.05 in order to analyze the data using the “Second Derivative 
maximum” method, where CPs are automatically identified and measured at the 
maximum acceleration of fluorescence. The above method was chosen instead of 
the “Fit Point method” as the second is influenced by the user, who has to determine 
the baseline adjustment, noice band setting, crossing line setting and choice of fit 
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points (Luu-The et al., 2005). “Second Derivative Maximum” is more precise in 
quantifying low gene expressions levels (Luu-The et al., 2005). 
4.2.8.2   Quantification analysis 
The principle of the relative quantification has already been explained in paragraph 
3.3.2. Quantification analysis uses the CP value of each sample, to determine the 
relative concentration of the target gene compared to a calibrator. Relative 
quantification analysis was performed using the “Relative quantification Mono-Color” 
(single channel) settings. As it has already been mentioned, an optimized external 
standard curve was imported for the evaluation of each run. The calculation of the 
CP values was made using the “Automated method” according to the 
recommendations of the manufacturer.  
 
 
 
4.3 Nested RT-PCR compared to RQ-PCR 
 
The aim of this study was to establish the possible role of RQ-PCR for MRD 
monitoring in AML patients bearing the RUNX1-RUNX1T1 fusion gene. The results 
were compared to nested RT-PCR which was performed in parallel as already 
mentioned. In total 184 samples were tested. Of these, 118 where positive and 66 
where negative in RQ-PCR. 
Interestingly, we observed a discrepancy in the results of RQ-PCR and nested RT-
PCR. One sample (1/118) was positive only in RQ-PCR and negative in RT-PCR.  
On the other hand, in the samples where no amplification was detected by RQ-PCR, 
24/66 were positive by nested RT-PCR.  
In cases where no amplification was observed in RT-PCR, more PCR template was 
used in the nested PCR reaction. 
When 5 μl of PCR template in nested reaction, gave no amplification, the reaction 
was repeated using 10 μl of primary PCR product. 
Unsurprisingly when 10 μL were used, the PCR sensitivity was rising and 5/24 
samples became positive (Fig 10). 
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Figure 10: Quantification of RUNX1-RUNX1T1 transcripts: a-1) quantification of 
RUNX/RUNX1T1 for sample 06-0904, b-1) primary and nested PCR for the same sample, a-2) 
quantification of RUNX/RUNX1T1 for the sample 06-0021, b-2) primary and nested PCR for 
the same sample 
 
a-1) 
 
 
b-1) 
 
 
a-2) 
 
 
 
b-2) 
 
447 bp 
205 bp 
205 bp 
447 bp 
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4.4 Application of the optimized RUNX1-RUNX1T1/ABL1 RQ-PCR   
protocol on t(8;21) positive AML patient samples 
 
4.4.1   Patients’ characteristics  
39 RUNX1-RUNX1T1 positive patients, that had been referred to the Laboratory for 
Leukemia Diagnostics, Klinikum Großhadern, were retrospectively investigated for 
routine cytogenetic and molecular analysis. Patients’ characteristics, cytogenetics 
and additional genetic alterations are listed in Table 4, 5 and 6, respectively on page 
25. 
The frequency of FLT3-ITD and FLT3-D835 mutation was 5.5% (2/36) and 2.7% 
(1/36), respectively (Schnittger et al., 2003, Schnittger et al., 2004). The KIT-D816 
mutation was found in 16.1% (5/31). None of the patients had the MLL-PTD mutation 
(Markova et al., 2009, Shen et al., 2011). 
 
4.4.2   RQ-PCR 
4.4.2.1   RUNX1-RUNX1T1 transcript levels at diagnosis  
29 patients were tested at diagnosis (28 BM samples and 1 PB). The RUNX1-
RUNX1T1 ratio ranged from 8.77 to 131.00 with a median of 29.37. 
 
4.4.2.2   MRD monitoring 
4.4.2.2.1   RUNX1-RUNX1T1 transcript levels at day 16 of the induction 
treatment 
RUNX1-RUNX1T1 levels were measured on day 16. 12 out of 39 samples were 
available (BM=11, PB=1). The levels of RUNX1-RUNX1T1 ratio ranged from 0.009 to 
28.96 with a median value of 2.11. In 6 patients, the reduction of the RUNX1-
RUNX1T1 transcript levels between diagnosis and d16 was only 1 log. 3 out of these 
6 patients relapsed. None of them had an early relapse (defined as relapse before 6 
months).  
4.4.2.2.2   RUNX1-RUNX1T1 transcript levels before consolidation 
23 patients were analyzed at about 2 months post diagnosis, before consolidation 
therapy (data not shown). The minimum value of RUNX1-RUNX1T1 ratio was 
0.00001 and the maximum was 0.52.   
20 out of 23 patients had paired samples at diagnosis and before consolidation. A 
decrease of RUNX1-RUNX1T1 expression between these two time points (3 logs) 
was observed in 18/20 patients and is presented in Fig 11 as green lines. Only three 
out of 18 patients (16.6%), with a 3-log reduction of RUNX1-RUNX1T1 expression 
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levels, relapsed. However only 2 patients had a less than 3 log reduction (Fig 11 red 
lines). Interestingly one of these two patients relapsed, but the group size was not 
sufficient for statistical analysis or calculation of cutoff-values for the relapsed risk.  
 
 
 
 
4.4.2.2.3   RUNX1-RUNX1T1 transcript levels at relapse  
The median follow up of the 39 patients was 24 months (range 1.7-71). Despite the 
favorable prognosis of t(8;21), 28% (11/39) of the patients in the study relapsed and 
5 of them, died. At relapse only 5 patient samples were available. Kinetics of MRD 
levels of the 5 relapsed patients are presented in Figure 12. The range of RUNX1-
RUNX1T1 transcripts was 0.12-35.19 (median 9.45). One of the patients (Fig12. pt 5) 
was found to be also positive for KIT-D816 mutation. Figure 13 (page 54), shows the 
RUNX1-RUNX1T1 fusion transcript levels at diagnosis, d16 of the treatment, before 
consolidation and at relapse. 
 
 
 
 
 
 
 
 
 
 
Figure 11: RUNX1-RUNX1T1 transcript levels at diagnosis and before consolidation 
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Figure 12: ratio levels of RUNX1-RUNX1T1 at relapse in 5 patients  
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Figure 13: RUNX1-RUNX1T1 transcript levels at different stages of the disease 
(patients=39) 
 
 
 
4.4.3 Application of nested RT-PCR on patient samples 
MRD monitoring of 18 patients, being in morphological CR after chemotherapy, is 
presented in Figure 14a. Six of these patients (pt 8, 9, 10, 13, 14 and pt 18) were 
nested PCR positive when checked one year after being in long term remission. 
Three out of these 6 patients (pt 9, 10, and pt. 18), had also detectable transcripts by 
RQ-PCR. 
None of these 6 patients relapsed within a follow up time of 18.8, 12, 46.8, 36.3, 41.9 
and 12 months, respectively.  
Although CBF leukemias, are considered favorable - risk diseases, additional 
mutations like KIT, as well as cytogenetic and clinical (e.g. chloroma) risk factors, 
may have negative impact on prognosis and therefore should be taken into 
consideration for patients suitable for BMT.  
MRD monitoring of nine patients after BMT, 8 patients after allogeneic BMT and one 
patient after BMT (Fig 14b, pt. 8), is presented in Figure 14b. In this cohort of 9 
patients, 4 were nested PCR positive for RUNX1-RUNX1T1 after BMT. Only one of 
them, (Fig 14b, pt. 4), became RQ-PCR positive 9 months after BMT, and relapsed 5 
months later. It is of notice, that a second patient (Fig 14b, pt. 5), being RQ- and 
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nested PCR positive post BMT, became negative seven months later using both 
methods.  
 
Figure 14: Comparison of RQ-PCR with RT-PCR at various check points. The blank 
triangle represents RQ-PCR negative samples, and the black RQ-PCR positive samples. 
The first cycle represents the primary PCR and the second cycle the nested PCR. 
Blank cycle indicates negative PCR and black cycles positive PCR.  Arrows indicate 
BMT. 
 
a) patients in remission after chemotherapy 
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b) patients received BMT 
 
 
4.5   RUNX1-RUNX1T1 in JAK2 positive myeloproliferative neoplasms  
 
In 2007, while the study was in progress a very interesting case report was studied at 
the Laboratory for Leukemia Diagnostics (Schneider et al., 2007). A 60 year old 
female patient was diagnosed in April 2004 with Polycythemia Vera. She had a 
normal karyotype and she was homozygous for JAK2V617F. Since then, she was 
treated by phlebotomy until February 2006 and then with hydroxyourea (HU). In July 
2007, despite the use of HU (for only 6 months), she developed leukocytosis and 
underwent new cytogenetic analysis which revealed an additional t(8;21). The result 
was confirmed by FISH analysis and RT-PCR. Although the role of HU in 
leukemogenesis cannot be ruled out it seems less probable due to the short use of it.  
This study provided for the first time a clear clinical evidence for the possible timely 
acquisitions of JAK2V617F mutation and RUNX1-RUNX1T1 fusion gene in a patient. 
As it is described in paragraph 1.2 (page 11), according to the “two-hit model” 
hypothesis of AML, RUNX1-RUNX1T1 and JAK2V617F may coexist, since both 
mutations may cooperate in leukemogenesis.  
It is known that JAK2V617F mutation is rare in de novo AML and little is known about 
the frequency of this mutation in specific cytogenetic risk groups of AML and about its 
impact on prognosis. 
To clarify the incidence and the prognostic significance of this additional mutation in 
our cohort, 18 patients were screened (Table 6, page 25) using melting curve 
analysis. No JAK2V617F mutation was detected. 
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5.  DISCUSSION  
 
5.1   RUNX1-RUNX1T1 RQ-PCR 
Nowadays, Real-time Quantitative RT-PCR (RQ-PCR) is the most popular method 
for the quantification of RNA in biological samples (Huggett et al., 2005). Furthermore, 
the method is highly sensitive and thus most suitable for MRD detection (Beillard et 
al., 2003). By performing a parallel amplification of a reference gene, known as 
housekeeping gene or endogenous control gene (Beillard et al., 2003), the RNA 
quality and quantity can be evaluated using the same technology.  
In order to supplement and verify molecular and standard cytogenetic diagnostics of 
RUNX1-RUNX1T1 fusion gene detection, our aim was to establish a fast and 
sensitive assay to detect and quantify RUNX1-RUNX1T1 transcripts at diagnosis and 
during follow-up. Thus, in contrast to nested PCR, a quantification of low transcript 
levels should be achieved. In this work, a quick (results in less than 1 hour), stable 
and accurate Taqman based RQ-PCR assay for RUNX1-RUNX1T1 and ABL1 
housekeeping gene was established and validated using the LightCycler platform 
and has been integrated in the routine diagnostic and follow-up of AML patients with 
t(8;21). Using this technology, the PCR amplification occurs in special closed glass 
capillaries, therefore the risk of contamination is very low.  
 
5.1.1   Choice of Reference gene 
To establish an accurate assay for quantitative MRD (RQ-PCR), it is of major 
importance to correct for sample to sample variations, variations in the integrity of 
RNA, differences due to RT-PCR efficiency and cDNA sample loading (Stahlberg et 
al., 2003, Stahlberg et al., 2004). Therefore, a housekeeping gene should be 
amplified in parallel to the target gene, ideally being optimized to run at the same 
conditions in the same run. This gene should be located on a chromosome which is 
not often involved in chromosome loss and gain, it should be expressed at similar 
levels in different cell types and it shouldn’t be connected to the cell cycle or to the 
cell activation (van der Velden et al., 2003).  
Within the Europe Against Cancer Program (Gabert et al., 2003), various genes were 
candidates for control genes. ABL1 (GenBank Accession Number M14752), was 
recommended as the most suitable gene for this purpose, since its expression is 
constant between BM and PB samples as well as between normal and leukemic 
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samples and shows no pseudogenes (van der Velden et al., 2003). ABL1 is located 
on the long chromosome of chromosome 9 (9q34) (Beillard et al., 2003). In this study, 
the PCR assay was optimized so that the amplification of the ABL1 reference gene 
and RUNX1-RUNX1T1 target gene had a similar efficiency and sensitivity as it is 
shown in Figure 8 (page 42) and 9 (page 44). The efficiency for the RUNX1-
RUNX1T1 amplification was 1.999 and for the ABL1 amplification the efficiency was 
1.973. 
 
5.1.2   Normalization of the assay 
RQ-PCR is a method that offers great accuracy in the quantification of the PCR 
product and is characterized by its high sensitivity. To achieve this, it is necessary to 
apply normalization strategies to the RQ-PCR data (Huggett et al., 2005). For this 
study, the first step was the normalization of the number of cells in the patient 
samples. Thus after isolation of PB mononuclear cells, cell counting was performed 
using the Microcell counter. Aliquots of 10x106 cells from samples at diagnosis and 
follow up respectively were used for RNA extraction. To ensure accurate 
quantification and qualification of RNA before reverse transcription, the amount of 
cells in RLT buffer, used to create cDNA, was the same for all diagnosis samples as 
well as for all the follow-up samples. This way, there was no need to perform 
normalization with RNA quantification before reverse transcription, as it is described 
by Hugget et al (Huggett et al., 2005). Possible degradation during storage of the 
lyzed cells or during RNA of cDNA synthesis steps needs to be normalized by the 
use of a reference gene.  
Some authors (Huggett et al., 2005) suggest the use of multiple reference genes, 
which is however often difficult to perform in routine diagnostics due to limited sample 
material and higher costs. Finally, normalization between different runs was achieved 
with the use of a calibrator. Τhe RUNX1-RUNX1T1/ABL1 expression ratios in all 
samples were divided by the RUNX1-RUNX1T1/ABL1 expression ratio of a calibrator 
(paragraph 4.2.2, page 40). Therefore, the ratio of target to reference gene for the 
calibrator should be constant.  
Target and reference genes showed stable expression in the cDNA from Kasumi-1 
cell line (that was used as calibrator), allowing the correction of variations in detection 
sensitivity due to sample quality between every run.  
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5.1.3   Sensitivity and reproducibility  
Maximum sensitivity is defined as the lowest dilution giving specific amplification. 
Sensitivity is affected by the number of cells examined, by the amount of RNA/cDNA 
that is analysed and by the number of PCR cycles (van der Velden et al., 2003).  
RQ-PCR assay for MRD analysis should reach a sensitivity of min 10-3 up to 10-4 and 
10-5 (van der Velden et al., 2003). Assays that target sequences such as FLT3-ITD 
and WT-1 reach sensitivities of at least 10-4 (van der Velden et al., 2003). Maximum 
sensitivity of 10-5 is observed in assays targeting a NPM1 mutation (Papadaki et al., 
2009).  
In this study the maximum sensitivity of the assays for both target and reference 
gene, was more than 10-4 (5x10-4) and found to be in accordance with Gabert J., et al 
(Gabert et al., 2003). The sensitivity of 5x10-4 was also confirmed using cDNA 
dilutions from Kasumi-1 cell line as well as dilutions (1:10-1:50000) of cDNA with 
known concentration from RUNX1-RUNX1T1 patients. Additionally 30 patient 
samples at various disease stages were amplified with RQ-PCR in order to further 
investigate the sensitivity of the assay (Table 16, page 46).  
In the study of MRD detection by van der Velden et al, (van der Velden et al., 2003) it 
is clear that the standard curve obtained by the 10 fold dilutions, should have a slope 
of -3.3. Thus when the logarithmic value of the dilution is plotted against the CP value, 
a standard curve with a slope of the of -3.3 is created and corresponds to maximum 
efficiency of 2.0. In practice slopes between -3.0 and -3.9 are acceptable (van der 
Velden et al., 2003). In this assay, the slope of the standard curve of the target gene 
was -3.32 and for the reference gene was -3.48, showing a good linearity and 
reproducibility. Standard curves are presented in Figure 9 a and b, page 44.  
 
 
5.2   Comparison of RQ-PCR to qualitative PCR 
 
The results of the quantitative PCR were in accordance with the results of the  
primary PCR, but the sensitivity of RQ-PCR was lower, compared to the nested PCR, 
since 24 samples were negative by RQ-PCR but positive by nested RT-PCR, as it is 
shown in Figure 14a and b, page 55 and 56.  
6 patients were positive in nested PCR although they were in a long term remission 
≥12 months. Interestingly in one patient who underwent BMT, we observed the same 
discrepancy in the results of quantitative and qualitative PCR. It is of notice that this 
patient had a morphological relapse 5 months later.  
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Several studies in the past have described the persistence of RUNX1-RUNX1T1 
transcripts by nested RT-PCR, in patients being in long term remission, even after 
BMT. 
Consequently, if the sensitivity of the RQ-PCR is very high, detection of MRD can be 
troubled. 
Miyamoto et al (Miyamoto et al., 1996), examined 22 patients with RT-PCR. 18 
patients were positive although they were in remission for 12-150 months. 4 of the 
patients had undergone allogeneic BMT. These positive results were attributed to the 
presence of residual multipotent hematopoietic progenitors retaining the t(8;21).  
Saunders et al (Saunders et al., 1994), reported 6 patients (in a cohort of 7), studied 
with RT-PCR, to be positive for the chimeric gene RUNX1-RUNX1T1 while being in 
remission. 2 patients were transplanted (1 patient with allogeneic BMT and the other 
with autologous BMT). 
Jurlander et al (Jurlander et al., 1996) presented the detection of AML-ETO 
transcripts with RT-PCR in 9 of 10 patients in CR after BMT, suggesting that the 
fusion transcript itself is not capable of inducing malignant transformation. 
Zhang et al (Zhang et al., 2013), recently screened, BM samples from 52 patients. 32 
patients were examined using nested RT-PCR (qualitative evaluation) and 20 
patients were examined with RQ-PCR (quantitative evaluation). Interestingly, the 
authors report that the results of the nested RT-PCR were of great prognostic value 
in the following time intervals: 6-12 months and 12-18 months. Patients with negative 
RUNX1-RUNX1T1 transcripts and duration of CR>1 year had low probability to 
relapse. They concluded that continuous negative results with RT-PCR indicate low 
risk of relapse. 
However, the number of patients included in these reports was small. 
 
 
5.3   Impact of prognostic factors in disease progression 
 
Despite the fact that AML with t(8;21) has a favorable prognosis, 28% of patients in 
this study relapsed, a result that is in accordance with the literature (Yin et al., 2012, 
Leroy et al., 2005, Schnittger et al., 2003).  
Among the ‘’classical’’ adverse prognostic factors for the disease, are the high WBC, 
as well as the age at diagnosis, as observed by a number of researchers.  
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For the relapsed patients in the study, the median WBC was 7x103/μL (min 
2.6x103/μL- max 43x103/μL) and the median age at diagnosis was 52.2 years (range: 
15,8-63,5).   
Nguyen et al (Nguyen et al., 2002) analyzed 161 patients of the French AML 
Intergroup, and observed that patients with low WBC index (WBC ratio to marrow 
blast), had a better prognosis.  
Martin et a (Martin et al., 2000), commented that WBC count had a significant 
prognostic influence on DFS.  
Recently Hoyos et al (Hoyos et al., 2013) reported a cut-off value of 20x103/μL in 
WBC at diagnosis, as a prognostic factor. They also comment that for patients above 
the age of 50, the current therapeutic protocols are not sufficient enough.  
As it is presented in Table 6 (page 25), KIT-D816 mutation was detected in 5/36 
patients (13.8%) in this study. Patients harboring the mutation presented at diagnosis 
with median WBC 13.3x103/μL (min 6.9x103/μL-max 31.7x103/μL). Although the 
sample of our study is small, the presence of KIT-D816 mutation was observed in 1 
of the relapsed patients. Additionally from the 39 patients participating in the study 
FLT3-ITD mutation was observed in two and FLT3-D835 in one patient (Table 6). 
KIT-D816 mutation has been recently recognized as an adverse prognostic factor  in 
RUNX1-RUNX1T1 positive AML (Dohner and Dohner, 2008, Schnittger et al., 
2006b).  
Schnittger et al (Schnittger et al., 2006b), reported the presence, as well as the 
unfavorable impact in prognosis of the KIT-D816 mutation, in 24,2% of RUNX1-
RUNX1T1 positive patients, from a cohort of 1940 randomly selected AML patients. 
The authors suggested that patients harboring this mutation are candidates for more 
intense or targeted treatments with tyrosine kinase inhibitors. In the same study 
however, FLT3 mutations were rarely detected in this subgroup of AML. 
The adverse prognostic significance of KIT-D816 mutation in CBF leukemias was 
also suggested by two other studies. In the first study, Cairoli et al (Cairoli et al., 
2006) analyzed 67 adults. They found an incidence of 45% (19/42) among the 
patients with t(8;21) which was associated with higher white blood cell count at 
diagnosis, higher incidence of extramedullary leukemia, higher incidence of relapse 
and inferior OS. In the second study 121 Korean patients were retrospectively 
evaluated by Kim et al (Kim et al., 2013). Here the incidence of the mutation was 
lower 27% (22/82) in patients with t(8;21), however the negative predictive value in 
event-free survival (EFS) and OS was maintained. 
This is in contrast with the experience of Riera et al (Riera et al., 2013) and Jones et 
al (Jones et al., 2010) who did not detect any difference in progress-free survival 
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(PFS) and OS, among CBF AML patients with additional KIT-D816 mutation. The 
frequency of the mutation found was 30.4% and 20% respectively. 
Very recently Krauth et al (Krauth et al., 2014), analyzed 139 patients with t(8;21) 
positive AML, for mutations in ASXL1, FLT3, KIT, NPM1, MLL, IDH1, IDH2, KRAS, 
NRAS, CBL and JAK2. Notably 69/139 patients (49.6%), had an additional molecular 
mutation. KIT mutations were the most common, found in 16.5% of the patients and 
had adverse prognostic impact in OS. Mutations of the ASXL1 were found in 11.5% 
of the patients and had adverse prognostic impact in EFS. JAK2 was detected in 
4/139 patients (2.9%) and FLT3-ITD in 7/9 patients (5%). 
In 2013 Opatz et al (Opatz et al., 2013), reported for the first time, the presence of 
FLT3-N676K mutation in CBF leukemias at diagnosis, without concurrent FLT3-ITD 
mutation. The mutation was detected in one patient with t(8;21) 1/36 (3%) and in 5/84 
(6%) patients with CBFB-MYH11. Although the number of FLT3-N676K positive 
patients is small, and the prognostic significance of the mutation has to be further 
evaluated, the authors report a tendency for lower CR rates in these patients.  
 
 
5.4   Monitoring MRD in AML with t(8;21) by RQ-PCR  
 
A lot of effort is being made to identify prognostic risk factors and evaluate the 
prognostic value for MRD monitoring. 
RQ-PCR is a well-established method with a wide range of applications in medicine 
and it is used routinely for the quantification of hybrid genes, as for PML-RARA 
resulting from the translocation t(15;17). Therefore the development of sensitive and 
specific RQ-PCR assays suitable for routine MRD monitoring, such as quantitative 
PCR for NPM1A (the most common mutation in the NPM1 gene) (Papadaki et al., 
2009), will help identify the group of patients in higher risk of relapse and based on 
that will help to make therapeutic interventions. MRD directed therapy at the moment 
is restricted to APL (Grimwade et al., 2009).  
The persistence of RUNX1-RUNX1T1 fusion transcripts in patients being in long term 
remission, brings up many questions regarding the prognostic significance of 
RUNX1-RUNX1T1 transcript quantification and the use of this method for MRD 
assessment. 
It is well known that the amount of residual leukemic blasts in the BM, one week after 
the end of the induction therapy (Kern et al., 2003) is of major prognostic significance, 
since it reflects the chemosensitivity of the disease. Thus, in our study transcript 
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levels were measured on day 16 and were correlated with the disease outcome. The 
median value was 2.11 (range 0.009-28.96). A reduction of only one log was 
observed in 6 patients and three of them relapsed. None had an early relapse.  
At about 2 months post diagnosis, before consolidation therapy, 23 patients were 
analyzed. Comparison of the levels at diagnosis and before consolidation, on 20 out 
of the 23 patients (as shown in Figure 11, page 51) revealed a statistically significant 
decrease of 3 logs, in the median value of RUNX1-RUNX1T1 ratios, in 18/20 patients. 
Only three patients with such a pronounced decrease relapsed. 
Tobal et al (Tobal et al., 2000) studied 25 patients with t(8;21) and found that a 2 to 3 
logs reduction of the RUNX1-RUNX1T1 fusion transcripts after induction treatment 
followed by another reduction for 2 to 3 logs after consolidation therapy, is of major 
clinical importance. Thus, regular monitoring of patients will help to early identify 
patients being at risk for relapse. The same investigators also reported an early 
intervention to prevent relapse based on MRD levels, in one patient after allogeneic 
BMT. The patient presented with increasing RUNX1-RUNX1T1 transcript levels 22 
months after transplantation, suggesting imminent hematologic relapse. Thus the 
authors decided to stop immunosuppressive treatment, resulting in acute Graft-
versus-host disease (GVHD) leading to complete clinical remission.  
Schnittger et al (Schnittger et al., 2003) studied 349 patients positive for RUNX1-
RUNX1T1, CBFB-MYH11 and PML-RARA, and evaluated the prognostic significance 
of quantifying fusion transcript levels using RQ-PCR. They conclude that the 
transcript levels at diagnosis as well as their log reduction <3, after consolidation 
identifies the patients being at high risk of relapse.  
Weisser et al (Weisser et al., 2007) investigated the outcome of 45 t(8;21) positive 
RUNX1-RUNX1T1 patients investigating the reduction of RUNX1-RUNX1T1 levels 
after induction and consolidation therapies. In this study the RUNX1-RUNX1T1 levels 
at the diagnosis did not influence the molecular response. Instead a reduction of 4 
logs of the transcript levels after induction and consolidation therapy was of major 
prognostic significance. Thus the importance of RUNX1-RUNX1T1 transcript levels 
at diagnosis is controversial since as shown in our assay too, the RUNX1-RUNX1T1 
transcript levels at diagnosis do not correlate with the clinical outcome of the patients. 
At diagnosis the levels of the transcripts for the patients who remained in CR had a 
median value 66.1 (range 8.77-131) and those for the relapsed patients had a 
median value 54.9 (range 12.84-65.41). 
In 2012, within the MRC AML-15 trial, Liu Yin et al (Yin et al., 2012), reported that the 
presence of low levels of RUNX1-RUNX1T1 copies in BM or PB at diagnosis 
correlate with a complete disease remission. Besides that, the increment of MRD 
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levels during follow up, predicts clinical relapse. The most important prognostic factor 
to predict relapse, is a log reduction of the transcripts in the bonne marrow less than 
3 (<3) after induction treatment. The study evaluated 163 patients with t(8;21). 
Recently, the results of the CBF-2006 trial (Jourdan et al., 2013) were published. 198 
patients with CBF leukemias were randomized between an induction treatment and a 
reinforced one, with the consolidation courses being the same for both groups. The 
MRD response after the first consolidation (3-log reduction and the absolute levels of 
0.1%) was the major prognostic factor of relapse. Specific mutations in the KIT and 
the FLT3 genes and a high WBC count at diagnosis were shown to be relatively 
weak prognostic factors for relapse prediction. 
Zhu et al (Zhu et al., 2013), report that MRD-directed risk stratification treatment may 
improve the prognosis of patients with t(8;21). They analysed 116 patients and they 
suggested that log reduction of RUNX1-RUNX1T1 transcripts <3 after the second 
consolidation, identifies patients belonging to the high risk group.  
In conclusion, our study supports the importance of MRD monitoring with RUNX1-
RUNX1T1 fusion gene. We were able to show that clinical outcome is related to the 
transcript levels measured on day 16, and to the log reduction (3-logs) measured 
between diagnosis and before consolidation therapy (paragraph 4.4.2.2.2, page 50). 
However the importance of transcript levels at diagnosis itself requires further 
confirmation.  
 
 
5.5   RUNX1-RUNX1T1 and JAK2V617F mutation 
 
The case report that was studied at the Laboratory for Leukemia Diagnostics in 2007 
(Schneider et al., 2007), provided for the first time a clear clinical evidence for the two 
hit model of leukemogenesis, in a leukemia patient with preexisting MPN.  
Here, we screened 18 t(8;21) positive patients for the presence of an additional 
JAK2V617F mutation, using melting curve analysis. We found no additional 
JAK2V617F in our small cohort (Table 6, page 25). This might be explained by the 
fact that all investigated patients had de novo AML.  
It is well established that in about 0.5-6% of RUNX1-RUNX1T1 positive patients, 
JAK2V617F point mutation is detected (Dohner et al., 2006, Steensma et al., 2006, 
Steensma et al., 2005). 
Vicente et al (Vicente et al., 2007), screened 339 AML patients at diagnosis and 
found 3.2% frequency of the mutation. Interestingly a correlation of the mutation with 
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less differentiated leukemias is mentioned, since all the positive patients were 
classified as M1 and M2 according to FAB. 
Schnittger et al (Schnittger et al., 2007b) screened 1372 patients with various chronic 
myeloproliferative disorders (CMPD). 178 patients had de novo AML and 11 of them 
were positive for the mutation. However, this cohort includes all the cytogenetic 
groups. From the 39 patients with therapy related AML (t-AML), 2 were found to be 
positive for the JAK2V617F.  
Schnittger et al (Schnittger et al., 2007a) further screened 24 patients positive for 
t(8;21), of which 20 patients had de novo AML, 1 patient had de novo AML in relapse 
and 3 patients had t-AML. Interestingly, 2 of the 3 patients with t-AML additionally 
had a JAK2V617F mutation, suggesting that JAK2V617F might be an additional 
aberration in t-AML. 
Further results on similar cases might help to clarify a risk for additional 
leukemogenic events associated with certain therapies. 
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6. SUMMARY 
 
 
 
Acute myeloid leukemia (AML) with t(8;21) rearrangement, constitutes about 5% of 
all AML cases and is characterized by the presence of RUNX1-RUNX1T1 fusion 
gene. Although this subtype, referred as CBF leukemia, belongs to the favorable 
cytogenetic risk group, 25% to 30% of the patients relapse. Detection of minimal 
residual disease (MRD) is of major importance since it evaluates the “depth” of the 
remission and therefore, risk adapted therapy based on early detection of relapse 
becomes feasible. RUNX1-RUNX1T1 fusion gene could be used for MRD detection 
using RQ-PCR.  
Within this work, a sensitive, specific and easy to perform, calibrator normalized 
relative quantification with external standards assay for RUNX1-RUNX1T1 transcript 
levels, was established and has consequently been integrated in the routine 
diagnostic work-up of RUNX1-RUNX1T1 positive patients. ABL1 was used as a 
reference gene and cDNA of the Kasumi-1 cell line as a calibrator. Relative 
quantification was performed by calculating the RUNX1-RUNX1T1/ ABL1 ratio, which 
was further normalized to the RUNX1-RUNX1T1/ABL1 expression ratio of Kasumi-1 
calibrator. Maximum sensitivity of the assays for both target and reference gene, was 
higher than 10-4 (5x10-4). The sensitivity of 5x10-4 was also confirmed using cDNA 
dilutions from Kasumi-1 cell line as well as dilutions of patients’ cDNA. The specificity 
of the assay was determined when RUNX1-RUNX1T1 negative patients were tested; 
along with cDNA from negative cell lines and no amplification was observed.  
184 samples from 39 patients, were quantified in order to assess the clinical 
usefulness of the assay. Transcript levels in 12 patients were measured on day 16 
and were correlated to the clinical outcome. Moreover in 20 patients, comparison of 
the RUNX1-RUNX1T1 ratios at diagnosis and before consolidation revealed a 3 log10 
decrease, which was also correlated to the disease outcome. 28% (11/39) of the 
patients in the study relapsed, consistent with previous studies. 
Very importantly, due to the good correlation of RUNX1-RUNX1T1 transcripts with 
the disease course, this assay will also be used to monitor MRD of t(8;21) positive 
patients within the recently launched AMLCG2014 study.  
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7. Zusammenfassung 
 
Die akute myeloische Leukämie (AML) mit t(8;21) macht ca. 5% aller AML Fälle aus 
und wird von der Präsenz des RUNX1-RUNX1T1 Fusionsgenes charakterisiert. 
Obwohl dieser Untertyp, der als CBF Leukämie bezeichnet ist, zu den günstigen 
cytogenetischen Riskgruppen gehört, erleiden 25% bis 30% der Patienten ein 
Rezidiv. Die Detektion der minimalen Resterkranknung (MRD) ist somit von großer 
Wichtigkeit, denn es erlaubt die Tiefe der Remission zu überprüfen.  
Eine risikoadaptierte Behandlung, die auf die frühe Detektion eines Rezidivs abzielt, 
ist mittels MRD konzeptionell machbar und sollte aus diesem Grund untersucht 
werden. Das AML-spezifische RUNX1-RUNX1T1 Fusionsgen kann mittels RQ-PCR 
für die MRD Detektion benutzt werden. 
In dieser Arbeit wurde eine sensitive, spezifische und leicht durchzuführende, mittels 
Kalibrator normalisierte, relative Quantifizierung  für das RUNX1-RUNX1T1 
Transkriptionstadium etabliert. Diese wurde im weiteren in der Diagnostik bei 
RUNX1-RUNX1T1 positiven Patienten benutzt. ABL1 wurde als Referenzgen und 
cDNA der Kasumi-1 Zelllinie als Kalibrator benutzt. Die relative Quantifizierung wurde 
mittels der RUNX1-RUNX1T1/ ABL1 Rate berechnet, welche weiterhin zur RUNX1-
RUNX1T1/ABL1 Expressionrate der Kasumi-1 Zellinie (Kalibrator) normalisiert wurde. 
Die maximale Sensitivität der Assays für beide Ziel- und Referenzgen war 5x10-4. 
Eine Sensitivität von 5x10-4 wurde sowohl mittels cDNA Verdünnungen von Kasumi-1 
Zelllinien, als auch von Verdünnungen des Patienten cDNA bestätigt.  
In 184 Proben von 39 Patienten wurde die Expression von RUNX1-RUNX1T1 
quantifiziert, um die klinische Nutzbarkeit des assays zu beurteilen. Die Expression 
wurde am Tag 16 nach Chemotherapie bei 12 Patienten gemessen und mit dem 
klinischen Ergebniss korreliert. Weiterhin wurde die RUNX1-RUNX1T1 Expression 
bei Erstdiagnose und vor Konsolidierung bei 20 Patienten bestimmt. Eine 3 log10 
Abnahme war mit einer geringen Rezidivwahrscheinlichkeit assoziiert. Insgesamt 
erlitten 28% (11/39) der Patienten in der Studie ein Rezidiv, was mit vorhergehenden 
Studien vereinbar ist.  
Die RUNX1-RUNX1T1 Expression kann mittels RQ-PCR monitorisiert werden und 
wird zur Quantifizierung der MRD bei t(8;21)-positiven-Patienten innerhalb der 
geplanten multizentrischen AMLCG2014 Studie verwendet werden.  
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   10. ABBREVIATIONS 
 
ALL acute lymphoblastic leukemia  
AML acute myeloid leukemia 
APL acute promyelocytic leukemia 
BM bone marrow 
BMT bone marrow transplantation 
bZIP basic region leucine zipper 
CBF core binding factor 
cDNA complementary DNA  
CEBPA  CCAAT/enhancer binding protein (C/EBP), alpha 
CML  chronic myelogenous leukemia  
CPp Crossing Point  
CR complete remission 
DFS disease- free survival 
dNTPs deoxynucleotide triphosphates  
dsDNA double-stranded DNA  
EFS event-free survival 
ET essential thrombocythemia  
ETO Eight-Twenty-One 
EVI1 Ecotropic viral integration-1  
FAB French - American – British 
FBS Fetal Bovine Serum  
FCS Fetal Culf Serum  
FISH fluorescence in situ hybridization  
FLT3 FMS-related tyrosine kinase 3 
FRET Fluorescence Resonance Energy Transfer  
G-CSF granulocyte - colony-stimulating factor 1 
HSCT haematopoietic stem cell transplantation  
IgH immunoglobulin heavy chain  
IL Interleukin  
ITD internal tandem duplication 
JAK Janus Kinase 
JH Janus Homology 
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MCSF macrophage colony stimulating factor 
MDR multidrug resistance 
MDS myelodysplastic syndrome 
MMM myelofibrosis with myeloid metaplasia 
MPD myeloproliferative disease 
MPO myeloperoxidase 
MRD minimal residual disease 
NHR nervy homology regions 
NK normal karyotype 
NPM nucleophosmin 
OS overall survival 
PB  peripheral blood 
PBMCs peripheral blood mononuclear cells  
PBS phosphate buffer saline  
PCR polymerase chain reaction 
PLT platelets 
PV polycythemia vera  
RAS ras-sarcoma protooncogen 
RFS relapse-free survival 
RHD Runt homology domain  
RQ-PCR Real time Quantitative PCR  
RT reverse transcription  
RTK receptor tyrosine kinase 
RT-PCR Reverse-Transcriptase PCR  
RUNX1 Runt-related transcription factor 1 
STAT signal transducer and activator of transcription 
Taq thermus aquaticus 
TCR T-cell receptor  
TK tyrosine kinase 
Tm melting temperature  
WBC white blood cells 
WHO World Health Organization 
WT Wilms tumor 
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